Alzheimerâs	alzheimerâs	CD	O
disease	disease	NNP	O
,	,	,	O
a	a	DT	O
progressive	progressive	JJ	O
and	and	CC	O
irreversible	irreversible	JJ	O
neurodegenerative	neurodegenerative	JJ	O
disorder	disorder	NN	O
,	,	,	O
is	be	VBZ	O
the	the	DT	O
most	most	RBS	O
common	common	JJ	O
cause	cause	NN	O
leading	lead	VBG	O
to	to	IN	O
memory	memory	NN	O
impairment	impairment	NN	O
and	and	CC	O
dementia	dementia	NN	O
in	in	IN	O
elderly	elderly	JJ	O
people	people	NNS	B
.	.	.	O

According	accord	VBG	O
to	to	IN	O
World	World	NNP	O
Alzheimer	Alzheimer	NNP	O
Report	Report	NNP	O
,	,	,	O
nearly	nearly	RB	O
50	50	CD	O
million	million	CD	O
people	people	NNS	O
worldwide	worldwide	RB	O
are	be	VBP	O
living	live	VBG	O
with	with	IN	O
dementia	dementia	NN	O
in	in	IN	O
2018	2018	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
number	number	NN	O
is	be	VBZ	O
likely	likely	JJ	O
to	to	TO	O
reach	reach	VB	O
152	152	CD	O
million	million	CD	O
by	by	IN	O
2050	2050	CD	B
.	.	.	O

This	this	DT	O
disease	disease	NN	O
has	have	VBZ	O
higher	high	JJR	O
use	use	NN	O
and	and	CC	O
costs	cost	NNS	O
of	of	IN	O
health	health	NN	O
care	care	NN	O
and	and	CC	O
long	long	JJ	O
-	-	HYPH	O
term	term	NN	O
care	care	NN	O
services	service	NNS	O
than	than	IN	O
other	other	JJ	O
conditions	condition	NNS	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
such	such	PDT	O
a	a	DT	O
large	large	JJ	O
number	number	NN	O
of	of	IN	O
patients	patient	NNS	O
will	will	MD	O
bring	bring	VB	O
heavy	heavy	JJ	O
burden	burden	NN	O
to	to	IN	O
public	public	JJ	O
health	health	NN	O
system	system	NN	O
in	in	IN	O
the	the	DT	O
future	future	NN	O
.	.	.	O

AD	ad	NN	O
was	be	VBD	O
first	first	RB	O
identified	identify	VBN	O
>	>	.	O
100âyears	100âyears	UH	O
ago	ago	RB	O
,	,	,	O
but	but	CC	O
the	the	DT	O
exact	exact	JJ	O
aetiology	aetiology	NN	O
is	be	VBZ	O
still	still	RB	O
largely	largely	RB	O
unknown	unknown	JJ	O
.	.	.	O

Many	many	JJ	O
clinical	clinical	JJ	O
hallmarks	hallmark	NNS	O
,	,	,	O
including	include	VBG	O
deficits	deficit	NNS	O
of	of	IN	O
acetylcholine	acetylcholine	NN	O
,	,	,	O
amyloid	amyloid	NN	O
-	-	HYPH	O
Î²	î²	NN	O
peptide	peptide	NN	O
deposits	deposit	NNS	O
,	,	,	O
oxidative	oxidative	JJ	O
stress	stress	NN	O
,	,	,	O
dyshomeostasis	dyshomeostasis	NN	O
of	of	IN	O
biometals	biometal	NNS	O
and	and	CC	O
hyperphosphorylated	hyperphosphorylate	VBN	O
tau	tau	NN	O
protein	protein	NN	O
,	,	,	O
are	be	VBP	O
thought	think	VBN	O
to	to	TO	O
be	be	VB	O
associated	associate	VBN	O
with	with	IN	O
the	the	DT	O
initiation	initiation	NN	O
and	and	CC	O
development	development	NN	O
of	of	IN	O
AD	ad	NN	O
.	.	.	O

Over	over	IN	O
the	the	DT	O
past	past	JJ	O
years	year	NNS	O
,	,	,	O
although	although	IN	O
great	great	JJ	O
efforts	effort	NNS	O
have	have	VBP	O
been	be	VBN	O
devoted	devote	VBN	O
to	to	TO	O
develop	develop	VB	O
novel	novel	JJ	O
drugs	drug	NNS	O
to	to	TO	O
treat	treat	VB	O
AD	ad	NN	O
by	by	IN	O
both	both	DT	O
pharmaceutical	pharmaceutical	NN	O
companies	company	NNS	O
and	and	CC	O
academic	academic	JJ	O
institutions	institution	NNS	O
,	,	,	O
no	no	DT	O
new	new	JJ	O
drugs	drug	NNS	O
have	have	VBP	O
entered	enter	VBN	O
the	the	DT	O
clinical	clinical	JJ	O
market	market	NN	O
and	and	CC	O
>	>	XX	O
200	200	CD	O
drug	drug	NN	O
candidates	candidate	NNS	O
ended	end	VBD	O
up	up	RP	O
with	with	IN	O
failure	failure	NN	O
in	in	IN	O
advanced	advanced	JJ	O
clinical	clinical	JJ	O
trials	trial	NNS	O
.	.	.	O

Currently	currently	RB	O
,	,	,	O
the	the	DT	O
clinical	clinical	JJ	O
treatment	treatment	NN	O
of	of	IN	O
AD	ad	NN	O
is	be	VBZ	O
mainly	mainly	RB	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
cholinergic	cholinergic	JJ	O
hypothesis	hypothesis	NN	O
,	,	,	O
which	which	WDT	O
states	state	VBZ	O
that	that	IN	O
improving	improve	VBG	O
the	the	DT	O
ACh	ACh	NNPS	O
level	level	NN	O
in	in	IN	O
brain	brain	NN	O
through	through	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
ACh	ACh	NNS	O
hydrolysis	hydrolysis	NN	O
can	can	MD	O
alleviate	alleviate	VB	O
the	the	DT	O
memory	memory	NN	O
loss	loss	NN	O
and	and	CC	O
cognitive	cognitive	JJ	O
decline	decline	NN	O
related	relate	VBN	O
to	to	IN	O
AD	ad	NN	B
,	,	,	B
.	.	.	O

At	at	IN	O
the	the	DT	O
neuronal	neuronal	JJ	O
level	level	NN	O
,	,	,	O
there	there	EX	O
are	be	VBP	O
two	two	CD	O
types	type	NNS	O
of	of	IN	O
cholinesterases	cholinesterase	NNS	O
that	that	WDT	O
can	can	MD	O
catalyse	catalyse	VB	O
ACh	ach	JJ	O
hydrolysis	hydrolysis	NN	O
,	,	,	O
namely	namely	RB	O
acetylcholinesterase	acetylcholinesterase	NN	O
and	and	CC	O
butyrylcholinesterase	butyrylcholinesterase	NN	B
.	.	.	O

However	however	RB	O
,	,	,	O
in	in	IN	O
contrast	contrast	NN	O
to	to	IN	O
AChE	AChE	''	O
,	,	,	O
BuChE	BuChE	NNP	O
is	be	VBZ	O
mainly	mainly	RB	O
distributed	distribute	VBN	O
in	in	IN	O
the	the	DT	O
peripheral	peripheral	JJ	O
areas	area	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
BuChE	BuChE	NNP	O
may	may	MD	O
cause	cause	VB	O
side	side	JJ	O
effect	effect	NN	O
in	in	IN	O
the	the	DT	O
peripheral	peripheral	JJ	O
system	system	NN	B
,	,	,	B
.	.	.	O

Thus	thus	RB	O
,	,	,	O
selective	selective	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
AChE	AChE	``	O
seems	seem	VBZ	O
more	more	RBR	O
beneficial	beneficial	JJ	O
for	for	IN	O
AD	ad	NN	O
treatment	treatment	NN	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
to	to	IN	O
cholinergic	cholinergic	JJ	O
hypothesis	hypothesis	NN	O
,	,	,	O
another	another	DT	O
hypothesis	hypothesis	NN	O
,	,	,	O
so	so	RB	O
-	-	HYPH	O
called	call	VBN	O
amyloid	amyloid	NN	O
-	-	HYPH	O
Î²	î²	NN	O
pathological	pathological	JJ	O
hypothesis	hypothesis	NN	O
,	,	,	O
has	have	VBZ	O
attracted	attract	VBN	O
great	great	JJ	O
interest	interest	NN	O
in	in	IN	O
recent	recent	JJ	O
years	year	NNS	B
.	.	.	O

This	this	DT	O
hypothesis	hypothesis	NN	O
posits	posit	NNS	O
that	that	IN	O
the	the	DT	O
gradual	gradual	JJ	O
accumulation	accumulation	NN	O
and	and	CC	O
aggregation	aggregation	NN	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
peptide	peptide	NN	O
in	in	IN	O
the	the	DT	O
brain	brain	NN	O
is	be	VBZ	O
a	a	DT	O
central	central	JJ	O
event	event	NN	O
that	that	WDT	O
results	result	VBZ	O
in	in	IN	O
neurodegeneration	neurodegeneration	NN	O
and	and	CC	O
dementia	dementia	NN	B
,	,	,	B
.	.	.	O

AÎ²	aî²	NN	O
peptides	peptide	NNS	O
consist	consist	VBP	O
of	of	IN	O
39â43	39â43	CD	O
residues	residue	NNS	O
,	,	,	O
which	which	WDT	O
are	be	VBP	O
generated	generate	VBN	O
via	via	IN	O
sequential	sequential	JJ	O
scission	scission	NN	O
of	of	IN	O
the	the	DT	O
amyloid	amyloid	NN	O
precursor	precursor	NN	O
protein	protein	NN	O
by	by	IN	O
Î²-	î²-	NN	O
and	and	CC	O
Î³-secretases	î³-secretase	NNS	O
.	.	.	O

AÎ²	aî²	NN	O
peptides	peptide	NNS	O
can	can	MD	O
aggregate	aggregate	VB	O
into	into	IN	O
monomers	monomer	NNS	O
,	,	,	O
oligomers	oligomer	NNS	O
and	and	CC	O
large	large	JJ	O
AÎ²	AÎ²	NNP	O
plaques	plaque	NNS	O
,	,	,	O
which	which	WDT	O
initiate	initiate	VBP	O
a	a	DT	O
neurodegenerative	neurodegenerative	JJ	O
cascade	cascade	NN	O
that	that	WDT	O
involves	involve	VBZ	O
inflammation	inflammation	NN	O
,	,	,	O
oxidative	oxidative	JJ	O
stress	stress	NN	O
,	,	,	O
and	and	CC	O
mitochondrial	mitochondrial	NN	O
dysfunction	dysfunction	NN	O
,	,	,	O
eventually	eventually	RB	O
leading	lead	VBG	O
to	to	IN	O
neuronal	neuronal	JJ	O
death	death	NN	O
and	and	CC	O
cognitive	cognitive	JJ	O
dysfunction	dysfunction	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
prevention	prevention	NN	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
provides	provide	VBZ	O
another	another	DT	O
therapeutic	therapeutic	JJ	O
approach	approach	NN	O
to	to	TO	O
halt	halt	VB	O
AD	ad	NN	O
pathogenesis	pathogenesis	NN	O
.	.	.	O

In	in	IN	O
fact	fact	NN	O
,	,	,	O
besides	besides	IN	O
the	the	DT	O
vital	vital	JJ	O
role	role	NN	O
in	in	IN	O
nerve	nerve	NN	O
transmission	transmission	NN	O
,	,	,	O
AChE	AChE	''	O
also	also	RB	O
plays	play	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
processing	processing	NN	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
peptides	peptide	NNS	B
.	.	.	O

The	the	DT	O
crystallographic	crystallographic	JJ	O
structure	structure	NN	O
of	of	IN	O
AChE	AChE	``	O
shows	show	VBZ	O
that	that	IN	O
it	-PRON-	PRP	O
has	have	VBZ	O
a	a	DT	O
nearly	nearly	RB	O
20âÃ	20âã	CD	O
deep	deep	JJ	O
narrow	narrow	JJ	O
gorge	gorge	NN	O
which	which	WDT	O
consists	consist	VBZ	O
of	of	IN	O
two	two	CD	O
binding	bind	VBG	O
sites	site	NNS	O
:	:	:	O
a	a	DT	O
catalytic	catalytic	JJ	O
active	active	JJ	O
site	site	NN	O
at	at	IN	O
the	the	DT	O
bottom	bottom	NN	O
of	of	IN	O
the	the	DT	O
gorge	gorge	NN	O
and	and	CC	O
a	a	DT	O
peripheral	peripheral	JJ	O
anionic	anionic	JJ	O
site	site	NN	O
near	near	IN	O
the	the	DT	O
entry	entry	NN	O
of	of	IN	O
the	the	DT	O
gorge	gorge	NN	B
.	.	.	O

Generally	generally	RB	O
,	,	,	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
bind	bind	VBP	O
to	to	IN	O
either	either	DT	O
one	one	CD	O
site	site	NN	O
can	can	MD	O
inhibit	inhibit	VB	O
the	the	DT	O
AChE.	AChE.	NNP	O
However	however	RB	O
,	,	,	O
recent	recent	JJ	O
reports	report	NNS	O
indicate	indicate	VBP	O
that	that	IN	O
,	,	,	O
apart	apart	RB	O
from	from	IN	O
catalysing	catalyse	VBG	O
ACh	ach	JJ	O
hydrolysis	hydrolysis	NN	O
,	,	,	O
the	the	DT	O
PAS	PAS	NNP	O
also	also	RB	O
has	have	VBZ	O
a	a	DT	O
close	close	JJ	O
relationship	relationship	NN	O
with	with	IN	O
the	the	DT	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
.	.	.	O

The	the	DT	O
PAS	PAS	NNP	O
can	can	MD	O
accelerate	accelerate	VB	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
and	and	CC	O
amyloid	amyloid	NN	O
fibril	fibril	NN	O
.	.	.	O

The	the	DT	O
interaction	interaction	NN	O
between	between	IN	O
AÎ²	AÎ²	NNP	O
and	and	CC	O
the	the	DT	O
PAS	PAS	NNP	O
produces	produce	VBZ	O
stable	stable	JJ	O
AChE	AChE	NNP	O
-	-	HYPH	O
AÎ²	aî²	NN	O
complexes	complex	NNS	O
,	,	,	O
which	which	WDT	O
are	be	VBP	O
more	more	RBR	O
toxic	toxic	JJ	O
than	than	IN	O
AÎ²	AÎ²	NNP	O
peptide	peptide	NN	O
aggregates	aggregate	NNS	B
,	,	,	B
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
dual	dual	JJ	O
binding	bind	VBG	O
site	site	NN	O
inhibitors	inhibitor	NNS	O
able	able	JJ	O
to	to	TO	O
interact	interact	VB	O
with	with	IN	O
both	both	CC	O
the	the	DT	O
CAS	CAS	NNP	O
and	and	CC	O
PAS	PAS	NNP	O
will	will	MD	O
be	be	VB	O
more	more	RBR	O
promising	promising	JJ	O
for	for	IN	O
treating	treat	VBG	O
AD	ad	NN	O
,	,	,	O
as	as	IN	O
they	-PRON-	PRP	O
can	can	MD	O
not	not	RB	O
only	only	RB	O
improve	improve	VB	O
cognition	cognition	NN	O
by	by	IN	O
inhibiting	inhibit	VBG	O
AChE	ache	RBS	O
,	,	,	O
but	but	CC	O
also	also	RB	O
provide	provide	VB	O
additional	additional	JJ	O
benefit	benefit	NN	O
through	through	IN	O
reducing	reduce	VBG	O
the	the	DT	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
induced	induce	VBN	O
by	by	IN	O
AChE.	ache.	NN	O
The	the	DT	O
basic	basic	JJ	O
precept	precept	NN	O
of	of	IN	O
designing	design	VBG	O
dual	dual	JJ	O
binding	binding	NN	O
site	site	NN	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
is	be	VBZ	O
to	to	TO	O
take	take	VB	O
three	three	CD	O
parts	part	NNS	O
to	to	TO	O
fulfil	fulfil	VB	O
the	the	DT	O
structural	structural	JJ	O
requirements	requirement	NNS	O
of	of	IN	O
AChE.	ache.	NN	O
The	the	DT	O
three	three	CD	O
parts	part	NNS	O
are	be	VBP	O
a	a	DT	O
PAS	PAS	NNP	O
binding	bind	VBG	O
moiety	moiety	NN	O
,	,	,	O
a	a	DT	O
CAS	cas	NN	O
binding	bind	VBG	O
moiety	moiety	NN	O
and	and	CC	O
a	a	DT	O
linker	linker	NN	O
connecting	connect	VBG	O
these	these	DT	O
two	two	CD	O
moieties	moiety	NNS	O
.	.	.	O

To	to	IN	O
date	date	NN	O
,	,	,	O
there	there	EX	O
are	be	VBP	O
four	four	CD	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
and	and	CC	O
one	one	CD	O
N	n	CD	O
-	-	HYPH	O
methyl	methyl	NN	O
-	-	HYPH	O
D	d	JJ	O
-	-	HYPH	O
aspartate	aspartate	NN	O
receptor	receptor	NN	O
antagonist	antagonist	NN	O
that	that	WDT	O
have	have	VBP	O
been	be	VBN	O
approved	approve	VBN	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
AD	ad	NN	O
in	in	IN	O
clinic	clinic	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
complex	complex	JJ	O
aetiology	aetiology	NN	O
of	of	IN	O
AD	ad	NN	O
,	,	,	O
these	these	DT	O
single	single	JJ	O
-	-	HYPH	O
target	target	NN	O
drugs	drug	NNS	O
can	can	MD	O
only	only	RB	O
achieve	achieve	VB	O
some	some	DT	O
temporary	temporary	JJ	O
amelioration	amelioration	NN	O
of	of	IN	O
the	the	DT	O
symptoms	symptom	NNS	O
instead	instead	RB	O
of	of	IN	O
slowing	slow	VBG	O
or	or	CC	O
halting	halt	VBG	O
the	the	DT	O
disease	disease	NN	O
progress	progress	NN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
a	a	DT	O
more	more	RBR	O
appropriate	appropriate	JJ	O
approach	approach	NN	O
for	for	IN	O
treating	treat	VBG	O
this	this	DT	O
disease	disease	NN	O
is	be	VBZ	O
development	development	NN	O
of	of	IN	O
multifunctional	multifunctional	JJ	O
molecules	molecule	NNS	O
that	that	WDT	O
can	can	MD	O
simultaneously	simultaneously	RB	O
modulate	modulate	VB	O
multiple	multiple	JJ	O
targets	target	NNS	O
or	or	CC	O
pathways	pathway	NNS	O
related	relate	VBN	O
to	to	IN	O
AD	ad	NN	O
.	.	.	O

The	the	DT	O
most	most	RBS	O
popular	popular	JJ	O
method	method	NN	O
for	for	IN	O
obtaining	obtain	VBG	O
these	these	DT	O
molecules	molecule	NNS	O
is	be	VBZ	O
to	to	TO	O
design	design	VB	O
a	a	DT	O
dual	dual	JJ	O
binding	binding	NN	O
site	site	NN	O
AChE	AChE	``	O
inhibitor	inhibitor	NN	O
and	and	CC	O
make	make	VB	O
it	-PRON-	PRP	O
exert	exert	VB	O
additional	additional	JJ	O
activities	activity	NNS	O
because	because	IN	O
of	of	IN	O
the	the	DT	O
fragments	fragment	NNS	O
introduced	introduce	VBN	O
.	.	.	O

The	the	DT	O
quinolinone	quinolinone	NN	O
scaffold	scaffold	NN	O
is	be	VBZ	O
prevalent	prevalent	JJ	O
in	in	IN	O
a	a	DT	O
variety	variety	NN	O
of	of	IN	O
pharmacologically	pharmacologically	RB	O
active	active	JJ	O
synthetic	synthetic	JJ	O
and	and	CC	O
natural	natural	JJ	O
compounds	compound	NNS	B
.	.	.	O

The	the	DT	O
reported	report	VBN	O
biological	biological	JJ	O
activities	activity	NNS	O
of	of	IN	O
quinolinone	quinolinone	NNP	O
derivatives	derivative	NNS	O
including	include	VBG	O
antioxidation	antioxidation	NN	O
,	,	,	O
anti	anti	JJ	O
-	-	JJ	O
osteoporosis	osteoporosis	JJ	O
,	,	,	O
anti	anti	JJ	O
-	-	JJ	O
influenza	influenza	JJ	O
and	and	CC	O
anticancer	anticancer	NN	O
activities	activity	NNS	O
,	,	,	O
etc	etc	FW	O
.	.	.	B
.	.	.	O

Recent	recent	JJ	O
studies	study	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
several	several	JJ	O
quinolinone	quinolinone	NN	O
derivatives	derivative	NNS	O
also	also	RB	O
presented	present	VBD	O
potent	potent	JJ	O
AChE	AChE	``	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
,	,	,	O
and	and	CC	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
quinolinone	quinolinone	NNP	O
moiety	moiety	NNP	O
could	could	MD	O
bind	bind	VB	O
to	to	IN	O
the	the	DT	O
PAS	PAS	NNP	O
through	through	IN	O
a	a	DT	O
Ï-Ï	Ï-Ï	NNP	O
stacking	stack	VBG	O
interaction	interaction	NN	B
,	,	,	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
it	-PRON-	PRP	O
can	can	MD	O
serve	serve	VB	O
as	as	IN	O
a	a	DT	O
PAS	PAS	NNP	O
binding	bind	VBG	O
moiety	moiety	NN	O
for	for	IN	O
design	design	NN	O
of	of	IN	O
dual	dual	JJ	O
binding	bind	VBG	O
site	site	NN	O
inhibitor	inhibitor	NN	O
.	.	.	O

On	on	IN	O
the	the	DT	O
other	other	JJ	O
hand	hand	NN	O
,	,	,	O
dithiocarbamate	dithiocarbamate	NN	O
is	be	VBZ	O
a	a	DT	O
versatile	versatile	JJ	O
pharmacophore	pharmacophore	NN	O
,	,	,	O
which	which	WDT	O
has	have	VBZ	O
been	be	VBN	O
receiving	receive	VBG	O
intense	intense	JJ	O
attention	attention	NN	O
in	in	IN	O
recent	recent	JJ	O
years	year	NNS	O
.	.	.	O

Very	very	RB	O
recently	recently	RB	O
,	,	,	O
our	-PRON-	PRP$	O
group	group	NN	O
found	find	VBD	O
that	that	IN	O
this	this	DT	O
moiety	moiety	NN	O
could	could	MD	O
interact	interact	VB	O
with	with	IN	O
CAS	CAS	NNP	O
of	of	IN	O
AChE	AChE	NNP	O
,	,	,	O
and	and	CC	O
many	many	JJ	O
compounds	compound	NNS	O
possessing	possess	VBG	O
this	this	DT	O
moiety	moiety	NN	O
also	also	RB	O
displayed	display	VBD	O
promising	promising	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	B
,	,	,	B
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
unlike	unlike	IN	O
the	the	DT	O
benzyl	benzyl	NNP	O
piperidine	piperidine	NN	O
of	of	IN	O
donepezil	donepezil	NNP	O
or	or	CC	O
tacrine	tacrine	JJ	O
that	that	WDT	O
have	have	VBP	O
been	be	VBN	O
widely	widely	RB	O
used	use	VBN	O
as	as	IN	O
CAS	cas	NN	O
binding	bind	VBG	O
group	group	NN	O
for	for	IN	O
design	design	NN	O
of	of	IN	O
multifunctional	multifunctional	JJ	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
,	,	,	O
the	the	DT	O
dithiocarbamate	dithiocarbamate	NN	O
is	be	VBZ	O
still	still	RB	O
rarely	rarely	RB	O
used	use	VBN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
interesting	interesting	JJ	O
to	to	TO	O
explore	explore	VB	O
this	this	DT	O
scaffold	scaffold	NN	O
as	as	IN	O
a	a	DT	O
CAS	cas	NN	O
binding	bind	VBG	O
group	group	NN	O
to	to	TO	O
design	design	VB	O
multifunctional	multifunctional	JJ	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
facts	fact	NNS	O
and	and	CC	O
considerations	consideration	NNS	O
mentioned	mention	VBN	O
above	above	RB	O
,	,	,	O
in	in	IN	O
present	present	JJ	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
attempted	attempt	VBD	O
to	to	TO	O
connect	connect	VB	O
quinolinone	quinolinone	NNP	O
fragment	fragment	NN	O
with	with	IN	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NN	O
to	to	TO	O
design	design	VB	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
new	new	JJ	O
compounds	compound	NNS	O
as	as	IN	O
multifunctional	multifunctional	JJ	O
dual	dual	JJ	O
binding	binding	NN	O
site	site	NN	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
AD	ad	NN	O
.	.	.	O

The	the	DT	O
quinolinone	quinolinone	NN	O
was	be	VBD	O
selected	select	VBN	O
to	to	TO	O
inhibit	inhibit	VB	O
AChE	AChE	''	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
by	by	IN	O
binding	bind	VBG	O
to	to	IN	O
PAS	PAS	NNP	O
,	,	,	O
while	while	IN	O
the	the	DT	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NNP	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
inhibit	inhibit	VB	O
AChE	AChE	``	O
through	through	IN	O
interacting	interacting	NN	O
with	with	IN	O
the	the	DT	O
CAS	cas	NN	O
.	.	.	O

A	a	DT	O
flexible	flexible	JJ	O
linker	linker	NN	O
was	be	VBD	O
exploited	exploit	VBN	O
to	to	TO	O
connect	connect	VB	O
these	these	DT	O
two	two	CD	O
moieties	moiety	NNS	O
,	,	,	O
because	because	IN	O
such	such	JJ	O
linker	linker	NN	O
could	could	MD	O
allow	allow	VB	O
designed	design	VBN	O
compounds	compound	NNS	O
simultaneously	simultaneously	RB	O
bind	bind	VBP	O
to	to	IN	O
both	both	CC	O
CAS	CAS	NNP	O
and	and	CC	O
PAS	PAS	NNP	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
since	since	IN	O
our	-PRON-	PRP$	O
previous	previous	JJ	O
studies	study	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
compounds	compound	NNS	O
bearing	bear	VBG	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NNP	O
could	could	MD	O
efficiently	efficiently	RB	O
inhibit	inhibit	VB	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
,	,	,	O
these	these	DT	O
new	new	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
also	also	RB	O
expected	expect	VBN	O
to	to	TO	O
present	present	VB	O
similar	similar	JJ	O
activity	activity	NN	O
,	,	,	O
thereby	thereby	RB	O
exerting	exert	VBG	O
multifunctional	multifunctional	JJ	O
effects	effect	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
in	in	IN	O
our	-PRON-	PRP$	O
initial	initial	JJ	O
step	step	NN	O
,	,	,	O
a	a	DT	O
piperidine	piperidine	NN	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NN	O
was	be	VBD	O
first	first	RB	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
starting	starting	NN	O
fragment	fragment	NN	O
to	to	TO	O
explore	explore	VB	O
the	the	DT	O
optimal	optimal	JJ	O
linker	linker	NN	O
length	length	NN	O
,	,	,	O
because	because	IN	O
the	the	DT	O
previous	previous	JJ	O
studies	study	NNS	O
suggested	suggest	VBD	O
that	that	IN	O
this	this	DT	O
moiety	moiety	NN	O
could	could	MD	O
potently	potently	RB	O
and	and	CC	O
selectively	selectively	RB	O
inhibit	inhibit	VB	O
AChE.	ache.	CD	O
And	and	CC	O
once	once	IN	O
the	the	DT	O
optimal	optimal	JJ	O
length	length	NN	O
was	be	VBD	O
determined	determined	JJ	O
,	,	,	O
various	various	JJ	O
secondary	secondary	JJ	O
amine	amine	NN	O
groups	group	NNS	O
were	be	VBD	O
introduced	introduce	VBN	O
to	to	TO	O
dithiocarbamate	dithiocarbamate	VB	O
moiety	moiety	NN	O
for	for	IN	O
further	further	JJ	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationship	relationship	NN	O
studies	study	NNS	O
.	.	.	O

All	all	DT	O
designed	design	VBN	O
compounds	compound	NNS	O
were	be	VBD	O
synthesised	synthesise	VBN	O
and	and	CC	O
evaluated	evaluate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
ability	ability	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
ChEs	ChEs	NNP	O
and	and	CC	O
cross	cross	VB	O
the	the	DT	O
blood	blood	NN	O
-	-	HYPH	O
brain	brain	NN	O
barrier	barrier	NN	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
potential	potential	JJ	O
activities	activity	NNS	O
were	be	VBD	O
also	also	RB	O
chosen	choose	VBN	O
for	for	IN	O
studies	study	NNS	O
including	include	VBG	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
evaluation	evaluation	NN	O
of	of	IN	O
hAChE	hAChE	NNP	O
and	and	CC	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
,	,	,	O
kinetic	kinetic	JJ	O
study	study	NN	O
of	of	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
,	,	,	O
and	and	CC	O
molecular	molecular	JJ	O
modelling	modelling	NN	O
studies	study	NNS	O
of	of	IN	O
their	-PRON-	PRP$	O
binding	bind	VBG	O
modes	mode	NNS	O
with	with	IN	O
AChE	AChE	``	O
and	and	CC	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
compound	compound	NN	O
was	be	VBD	O
selected	select	VBN	O
to	to	TO	O
test	test	VB	O
its	-PRON-	PRP$	O
cytotoxicity	cytotoxicity	NN	O
in	in	IN	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
neuroblastoma	neuroblastoma	NN	O
cells	cell	NNS	O
and	and	CC	O
acute	acute	JJ	O
toxicity	toxicity	NN	O
in	in	IN	O
mice	mouse	NNS	O
.	.	.	O

Herein	Herein	NNP	O
,	,	,	O
we	-PRON-	PRP	O
report	report	VBP	O
the	the	DT	O
design	design	NN	O
,	,	,	O
synthesis	synthesis	NN	O
and	and	CC	O
evaluation	evaluation	NN	O
of	of	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
novel	novel	JJ	O
quinolinone	quinolinone	NNP	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NN	O
as	as	IN	O
multifunctional	multifunctional	JJ	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
AD	ad	NN	O
treatment	treatment	NN	O
.	.	.	O

Rational	rational	JJ	O
design	design	NN	O
of	of	IN	O
quinolinone	quinolinone	NN	O
derivatives	derivative	NNS	O
as	as	IN	O
multifunctional	multifunctional	JJ	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
AD	ad	NN	O
.	.	.	O

All	all	DT	O
reagents	reagent	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
suppliers	supplier	NNS	O
and	and	CC	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
unless	unless	IN	O
specified	specify	VBN	O
.	.	.	O

The	the	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
analytical	analytical	JJ	O
thin	thin	JJ	O
-	-	HYPH	O
layer	layer	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
Silica	Silica	NNP	O
Gel	Gel	NNP	O
aluminium	aluminium	NN	O
sheets	sheet	NNS	O
and	and	CC	O
visualised	visualise	VBN	O
with	with	IN	O
a	a	DT	O
UV	UV	NNP	O
lamp	lamp	NN	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
with	with	IN	O
an	an	DT	O
XT-4	XT-4	NNP	O
micromelting	micromelting	NN	O
point	point	NN	O
apparatus	apparatus	NN	O
and	and	CC	O
are	be	VBP	O
uncorrected	uncorrected	JJ	O
.	.	.	O

The	the	DT	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
ACF-600	acf-600	RB	O
spectrometer	spectrometer	VB	O
using	use	VBG	O
the	the	DT	O
tetramethylsilane	tetramethylsilane	NN	O
as	as	IN	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

High	high	JJ	O
resolution	resolution	NN	O
mass	mass	NN	O
spectra	spectra	NNP	O
were	be	VBD	O
taken	take	VBN	O
on	on	IN	O
a	a	DT	O
Triple	Triple	NNP	O
TOF	TOF	NNP	O
5600	5600	CD	O
spectrometer	spectrometer	NN	O
.	.	.	O

The	the	DT	O
intermediates	intermediate	NNS	O
2	2	CD	O
and	and	CC	O
7a	7a	NNP	O
-	-	HYPH	O
b	b	NNP	O
were	be	VBD	O
prepared	prepare	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
literature	literature	NN	O
methods	method	NNS	B
,	,	,	B
,	,	,	B
,	,	,	O
and	and	CC	O
the	the	DT	O
structures	structure	NNS	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
characterised	characterise	VBN	O
by	by	IN	O
mass	mass	JJ	O
spectra	spectra	NNP	O
.	.	.	O

Then	then	RB	O
,	,	,	O
to	to	IN	O
a	a	DT	O
mixture	mixture	NN	O
of	of	IN	O
2/7a	2/7a	CD	O
-	-	HYPH	O
b	b	NN	O
5.0âmmol	5.0âmmol	CD	O
and	and	CC	O
anhydrous	anhydrous	JJ	O
K2CO3	K2CO3	NNP	O
1.4âg	1.4âg	CD	O
,	,	,	O
10âmmol	10âmmol	CD	O
in	in	IN	O
acetone	acetone	NN	O
15âmL	15âml	CD	O
was	be	VBD	O
added	add	VBN	O
appropriate	appropriate	JJ	O
Î±	î±	NN	O
,	,	,	O
Ï-dibromoalkanes	Ï-dibromoalkanes	NNP	O
50âmmol	50âmmol	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
refluxed	refluxe	VBN	O
under	under	IN	O
stirring	stir	VBG	O
for	for	IN	O
4âh	4âh	CD	O
.	.	.	O

After	after	IN	O
completing	complete	VBG	O
,	,	,	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
filtered	filter	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
evaporated	evaporate	VBN	O
under	under	IN	O
reduced	reduce	VBN	O
pressure	pressure	NN	O
.	.	.	O

The	the	DT	O
obtained	obtained	JJ	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NN	O
chromatography	chromatography	NN	O
with	with	IN	O
PE	PE	NNP	O
/	/	SYM	O
EA	EA	NNP	O
as	as	IN	O
eluent	eluent	NN	O
to	to	TO	O
give	give	VB	O
compounds	compound	NNS	O
3a	3a	NNP	O
-	-	HYPH	O
e	e	NNP	O
and	and	CC	O
8a	8a	NNP	O
-	-	HYPH	O
b	b	NNP	O
as	as	IN	O
white	white	JJ	O
solid	solid	JJ	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
appropriate	appropriate	JJ	O
secondary	secondary	JJ	O
amine	amine	NN	O
1.2âmmol	1.2âmmol	CD	O
and	and	CC	O
TEA	TEA	NNP	O
131âmg	131âmg	CD	O
,	,	,	O
1.3âmmol	1.3âmmol	CD	O
in	in	IN	O
DMF	DMF	NNP	O
2âmL	2âml	CD	O
was	be	VBD	O
added	add	VBN	O
CS2	CS2	NNP	O
99âmg	99âmg	CD	O
,	,	,	O
1.3âmmol	1.3âmmol	CD	O
drop	drop	VBP	O
wise	wise	JJ	O
.	.	.	O

After	after	IN	O
stirring	stir	VBG	O
for	for	IN	O
5âmin	5âmin	CD	O
,	,	,	O
another	another	DT	O
solution	solution	NN	O
containing	contain	VBG	O
corresponding	correspond	VBG	O
2-quinolinone	2-quinolinone	CD	O
derivatives	derivative	NNS	O
3a	3a	NNP	O
-	-	HYPH	O
e	e	NNP	O
or	or	CC	O
8a	8a	NNP	O
-	-	HYPH	O
b	b	NNP	O
1.2âmmol	1.2âmmol	CD	O
in	in	IN	O
DMF	DMF	NNP	O
3âmL	3âml	CD	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
12âh	12âh	CD	O
.	.	.	O

After	after	IN	O
completing	complete	VBG	O
,	,	,	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
water	water	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
standard	standard	JJ	O
extraction	extraction	NN	O
procedure	procedure	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
crude	crude	JJ	O
product	product	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NN	O
chromatography	chromatography	NN	O
with	with	IN	O
PE	PE	NNP	O
/	/	SYM	O
EA	EA	NNP	O
as	as	IN	O
eluent	eluent	JJ	O
to	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
target	target	NN	O
compounds	compound	NNS	O
.	.	.	O

The	the	DT	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
test	test	NN	O
compounds	compound	NNS	O
against	against	IN	O
AChE	AChE	``	O
and	and	CC	O
BuChE	BuChE	NNP	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
the	the	DT	O
spectrophotometric	spectrophotometric	JJ	O
method	method	NN	O
of	of	IN	O
Ellman	Ellman	NNP	B
.	.	.	O

Acetylcholinesterase	acetylcholinesterase	NN	O
,	,	,	O
butyrylcholinesterase	butyrylcholinesterase	NN	O
,	,	,	O
S	s	NN	O
-	-	HYPH	O
butyrylthiocholine	butyrylthiocholine	NNP	O
iodide	iodide	NN	O
,	,	,	O
acetylthiocholine	acetylthiocholine	NN	O
iodide	iodide	NNP	O
,	,	,	O
5	5	CD	O
,	,	,	O
5â²-dithiobis	5â²-dithiobis	NNP	O
-	-	:	O
and	and	CC	O
the	the	DT	O
reference	reference	NN	O
compounds	compound	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
.	.	.	O

The	the	DT	O
compounds	compound	NNS	O
were	be	VBD	O
first	first	RB	O
prepared	prepare	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
and	and	CC	O
then	then	RB	O
diluted	dilute	VBN	O
with	with	IN	O
Tris	Tris	NNP	O
-	-	HYPH	O
HCl	HCl	NNP	O
buffer	buffer	NN	O
50âmM	50âmm	CD	O
,	,	,	O
pH	pH	NNP	O
=	=	SYM	O
8.0	8.0	CD	O
,	,	,	O
0.1âM	0.1âM	NNP	O
NaCl	NaCl	NNP	O
,	,	,	O
0.02âM	0.02âm	CD	O
MgCl2Â·6H2O	MgCl2Â·6H2O	NNP	O
to	to	TO	O
yield	yield	VB	O
corresponding	corresponding	JJ	O
test	test	NN	O
concentration	concentration	NN	O
.	.	.	O

For	for	IN	O
each	each	DT	O
assay	assay	NN	O
,	,	,	O
160âÎ¼L	160âî¼l	CD	O
of	of	IN	O
1.5âmM	1.5âmm	CD	O
DTNB	DTNB	NNP	O
,	,	,	O
50âÎ¼L	50âî¼l	CD	O
of	of	IN	O
AChE	AChE	NNP	O
0.22âU	0.22âU	NFP	O
/	/	SYM	O
mL	mL	NNP	O
for	for	IN	O
eeAChE	eeAChE	NNP	O
;	;	:	O
0.05âU	0.05âU	,	O
/	/	SYM	O
mL	mL	NNP	O
for	for	IN	O
hAChE	hAChE	NNP	O
or	or	CC	O
eqBuChE	eqBuChE	NNP	O
0.12âU	0.12âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
were	be	VBD	O
incubated	incubate	VBN	O
with	with	IN	O
10âÎ¼L	10âî¼l	CD	O
of	of	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
test	test	NN	O
compounds	compound	NNS	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
6âmin	6âmin	CD	O
.	.	.	O

After	after	IN	O
this	this	DT	O
,	,	,	O
30âÎ¼L	30âî¼l	CD	O
of	of	IN	O
substrate	substrate	NN	O
15âmM	15âmm	CD	O
,	,	,	O
ATCI	ATCI	NNP	O
or	or	CC	O
BTCI	BTCI	NNP	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
absorbance	absorbance	NN	O
was	be	VBD	O
measured	measure	VBN	O
with	with	IN	O
a	a	DT	O
wavelength	wavelength	NN	O
of	of	IN	O
405ânm	405ânm	CD	O
at	at	IN	O
different	different	JJ	O
time	time	NN	O
intervals	interval	NNS	O
0	0	CD	O
,	,	,	O
60	60	CD	O
,	,	,	O
120	120	CD	O
,	,	,	O
and	and	CC	O
180âs	180âs	NNP	O
.	.	.	O

The	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
each	each	DT	O
compound	compound	NN	O
was	be	VBD	O
tested	test	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
,	,	,	O
and	and	CC	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
graphically	graphically	RB	O
from	from	IN	O
percent	percent	NN	O
inhibition	inhibition	NN	O
curves	curve	NNS	O
,	,	,	O
using	use	VBG	O
the	the	DT	O
Graph	Graph	NNP	O
Pad	Pad	NNP	O
Prism	Prism	NNP	O
4.03	4.03	CD	O
software	software	NN	O
.	.	.	O

The	the	DT	O
parallel	parallel	JJ	O
artificial	artificial	JJ	O
membrane	membrane	NN	O
permeation	permeation	NN	O
assay	assay	NN	O
for	for	IN	O
blood	blood	NN	O
-	-	HYPH	O
brain	brain	NN	O
-	-	HYPH	O
barrier	barrier	NN	O
was	be	VBD	O
performed	perform	VBN	O
to	to	TO	O
predict	predict	VB	O
the	the	DT	O
BBB	BBB	NNP	O
penetration	penetration	NN	O
of	of	IN	O
test	test	NN	O
compounds	compound	VBZ	B
.	.	.	O

Before	before	IN	O
the	the	DT	O
experiments	experiment	NNS	O
,	,	,	O
all	all	DT	O
compounds	compound	NNS	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
,	,	,	O
and	and	CC	O
the	the	DT	O
stock	stock	NN	O
solutions	solution	NNS	O
were	be	VBD	O
diluted	dilute	VBN	O
in	in	IN	O
PBS	PBS	NNP	O
/	/	SYM	O
EtOH	EtOH	NNP	O
to	to	TO	O
make	make	VB	O
secondary	secondary	JJ	O
stock	stock	NN	O
solutions	solution	NNS	O
25âÎ¼g	25âÎ¼g	NNP	O
/	/	SYM	O
mL	ml	NN	O
.	.	.	O

After	after	IN	O
the	the	DT	O
pre	pre	NN	O
-	-	NN	O
treatment	treatment	NN	O
,	,	,	O
the	the	DT	O
filter	filter	NN	O
membrane	membrane	NN	O
on	on	IN	O
the	the	DT	O
96-well	96-well	CD	O
filtration	filtration	NN	O
plate	plate	NN	O
PVDF	PVDF	NNP	O
membrane	membrane	NN	O
,	,	,	O
pore	pore	NN	O
size	size	NN	O
0.45âmm	0.45âmm	NNP	O
,	,	,	O
Millipore	Millipore	NNP	O
was	be	VBD	O
coated	coat	VBN	O
with	with	IN	O
4âÎ¼L	4âî¼l	CD	O
of	of	IN	O
PBL	PBL	NNP	O
in	in	IN	O
dodecane	dodecane	NN	O
20âmg	20âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
,	,	,	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
.	.	.	O

Then	then	RB	O
,	,	,	O
300âÎ¼L	300âî¼l	CD	O
of	of	IN	O
PBS	PBS	NNP	O
/	/	SYM	O
EtOH	EtOH	NNP	O
and	and	CC	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
diluted	dilute	VBN	O
solution	solution	NN	O
containing	contain	VBG	O
the	the	DT	O
corresponding	correspond	VBG	O
drugs	drug	NNS	O
or	or	CC	O
test	test	NN	O
compounds	compound	NNS	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
corresponding	correspond	VBG	O
acceptor	acceptor	NN	O
well	well	RB	O
and	and	CC	O
donor	donor	NN	O
well	well	RB	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Afterwards	afterwards	RB	O
,	,	,	O
the	the	DT	O
acceptor	acceptor	NN	O
filter	filter	NN	O
plate	plate	NN	O
was	be	VBD	O
carefully	carefully	RB	O
placed	place	VBN	O
on	on	IN	O
the	the	DT	O
donor	donor	NN	O
plate	plate	NN	O
to	to	TO	O
make	make	VB	O
the	the	DT	O
coated	coat	VBN	O
membrane	membrane	NN	O
touch	touch	NN	O
both	both	DT	O
donor	donor	NN	O
solution	solution	NN	O
and	and	CC	O
acceptor	acceptor	NN	O
buffer	buffer	NN	O
.	.	.	O

After	after	IN	O
incubation	incubation	NN	O
for	for	IN	O
18âh	18âh	CD	O
at	at	IN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
the	the	DT	O
concentrations	concentration	NNS	O
of	of	IN	O
test	test	NN	O
compounds	compound	NNS	O
in	in	IN	O
reference	reference	NN	O
,	,	,	O
acceptor	acceptor	NN	O
and	and	CC	O
donor	donor	NN	O
wells	well	NNS	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
a	a	DT	O
UV	uv	NN	O
plate	plate	NN	O
reader	reader	NN	O
.	.	.	O

Pe	Pe	NNP	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
following	following	JJ	O
expression	expression	NN	O
:	:	:	O
Pe	Pe	NNP	O
=	=	SYM	O
{	{	-LRB-	O
âVdVa/[At]}ln	âVdVa/[At]}ln	NNP	O
,	,	,	O
where	where	WRB	O
Vd	Vd	NNP	O
is	be	VBZ	O
the	the	DT	O
volume	volume	NN	O
of	of	IN	O
donor	donor	NN	O
well	well	RB	O
,	,	,	O
Va	Va	NNP	O
is	be	VBZ	O
volume	volume	NN	O
in	in	IN	O
acceptor	acceptor	NN	O
well	well	RB	O
,	,	,	O
A	a	NN	O
is	be	VBZ	O
the	the	DT	O
filter	filter	NN	O
area	area	NN	O
,	,	,	O
t	t	NNP	O
is	be	VBZ	O
the	the	DT	O
permeation	permeation	NN	O
time	time	NN	O
,	,	,	O
drugacceptor	drugacceptor	NN	O
is	be	VBZ	O
the	the	DT	O
absorbance	absorbance	NN	O
obtained	obtain	VBN	O
in	in	IN	O
the	the	DT	O
acceptor	acceptor	NN	O
well	well	NN	O
and	and	CC	O
drugequilibrium	drugequilibrium	NN	O
is	be	VBZ	O
the	the	DT	O
theoretical	theoretical	JJ	O
equilibrium	equilibrium	NN	O
absorbance	absorbance	NN	O
.	.	.	O

Each	each	DT	O
compound	compound	NN	O
was	be	VBD	O
analysed	analyse	VBN	O
at	at	IN	O
five	five	CD	O
wavelengths	wavelength	NNS	O
in	in	IN	O
four	four	CD	O
wells	well	NNS	O
at	at	IN	O
least	least	RBS	O
three	three	CD	O
independent	independent	JJ	O
runs	run	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
results	result	NNS	O
were	be	VBD	O
expressed	express	VBN	O
as	as	IN	O
meanâÂ±âSD	meanâÂ±âSD	NNP	O
.	.	.	O

To	to	TO	O
determine	determine	VB	O
the	the	DT	O
inhibition	inhibition	NN	O
mechanism	mechanism	NN	O
of	of	IN	O
present	present	JJ	O
compounds	compound	NNS	O
,	,	,	O
compound	compound	NNP	O
4c	4c	CD	O
was	be	VBD	O
taken	take	VBN	O
for	for	IN	O
kinetic	kinetic	JJ	O
analysis	analysis	NN	O
by	by	IN	O
Ellmanâs	ellmanâs	CD	O
method	method	NN	B
.	.	.	O

Three	three	CD	O
concentrations	concentration	NNS	O
of	of	IN	O
4c	4c	CD	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
the	the	DT	O
study	study	NN	O
,	,	,	O
and	and	CC	O
hAChE	hAChE	NNP	O
was	be	VBD	O
chosen	choose	VBN	O
as	as	IN	O
enzyme	enzyme	NNS	O
source	source	NN	O
.	.	.	O

Following	follow	VBG	O
a	a	DT	O
similar	similar	JJ	O
method	method	NN	O
mentioned	mention	VBN	O
above	above	RB	O
in	in	IN	O
enzyme	enzyme	NNS	O
inhibition	inhibition	NN	O
assay	assay	NN	O
,	,	,	O
LineweaverâBurk	LineweaverâBurk	NNP	O
reciprocal	reciprocal	JJ	O
plots	plot	NNS	O
were	be	VBD	O
constructed	construct	VBN	O
by	by	IN	O
plotting	plot	VBG	O
1	1	CD	O
/	/	SYM	O
velocity	velocity	NN	O
against	against	IN	O
1	1	CD	O
/	/	SYM	O
at	at	IN	O
varying	vary	VBG	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
substrate	substrate	JJ	O
acetylthiocholine	acetylthiocholine	NN	O
0.05	0.05	CD	O
â	â	NNP	O
0.5âmM	0.5âmm	NN	O
.	.	.	O

All	all	DT	O
measurements	measurement	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
and	and	CC	O
data	datum	NNS	O
analysis	analysis	NN	O
was	be	VBD	O
performed	perform	VBN	O
with	with	IN	O
Graph	Graph	NNP	O
Pad	Pad	NNP	O
Prism	Prism	NNP	O
4.03	4.03	CD	O
software	software	NN	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
were	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
Molecular	Molecular	NNP	O
Operating	Operating	NNP	O
Environment	Environment	NNP	O
software	software	NN	O
package	package	NN	O
.	.	.	O

The	the	DT	O
crystal	crystal	NN	O
structures	structure	NNS	O
of	of	IN	O
hAChE	hache	NN	O
,	,	,	O
TcAChE	TcAChE	NNP	O
and	and	CC	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
were	be	VBD	O
downloaded	download	VBN	O
from	from	IN	O
PBD	PBD	NNP	O
.	.	.	O

All	all	DT	O
water	water	NN	O
molecules	molecule	NNS	O
from	from	IN	O
the	the	DT	O
protein	protein	NN	O
were	be	VBD	O
removed	remove	VBN	O
,	,	,	O
and	and	CC	O
hydrogen	hydrogen	NN	O
atoms	atom	NNS	O
were	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
ligands	ligand	NNS	O
were	be	VBD	O
constructed	construct	VBN	O
using	use	VBG	O
the	the	DT	O
builder	builder	NN	O
module	module	NN	O
in	in	IN	O
MOE	MOE	NNP	O
and	and	CC	O
were	be	VBD	O
further	further	RB	O
minimised	minimise	VBN	O
via	via	IN	O
MMFF94X	MMFF94X	NNP	O
force	force	NN	O
field	field	NN	O
.	.	.	O

After	after	IN	O
that	that	DT	O
,	,	,	O
the	the	DT	O
optimised	optimise	VBN	O
geometry	geometry	NN	O
of	of	IN	O
ligand	ligand	NNP	O
was	be	VBD	O
saved	save	VBN	O
as	as	IN	O
a	a	DT	O
file	file	NN	O
and	and	CC	O
docked	dock	VBN	O
into	into	IN	O
the	the	DT	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
the	the	DT	O
protein	protein	NN	O
using	use	VBG	O
the	the	DT	O
MOE	MOE	NNP	O
-	-	HYPH	O
Dock	Dock	NNP	O
programme	programme	NN	O
.	.	.	O

The	the	DT	O
London	London	NNP	O
dG	dG	NNP	O
and	and	CC	O
Rigid	Rigid	NNP	O
Receptor	Receptor	NNP	O
were	be	VBD	O
selected	select	VBN	O
as	as	IN	O
initial	initial	JJ	O
and	and	CC	O
final	final	JJ	O
scoring	score	VBG	O
methods	method	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
5	5	CD	O
poses	pose	NNS	O
of	of	IN	O
each	each	DT	O
ligand	ligand	NN	O
were	be	VBD	O
retained	retain	VBN	O
and	and	CC	O
scored	score	VBN	O
.	.	.	O

The	the	DT	O
MOE	MOE	NNP	O
's	's	POS	O
pose	pose	NN	O
viewer	viewer	NN	O
utility	utility	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
analyse	analyse	VB	O
the	the	DT	O
geometry	geometry	NN	O
of	of	IN	O
resulting	result	VBG	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
compounds	compound	NNS	O
4c	4c	NNP	O
-	-	HYPH	O
f	f	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
on	on	IN	O
AChE	AChE	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
were	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
a	a	DT	O
Thioflavin	Thioflavin	NNP	O
T	T	NNP	O
-binding	-binding	NN	O
assay	assay	NN	B
,	,	,	B
.	.	.	O

1	1	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
1	1	CD	O
,	,	,	O
3	3	CD	O
,	,	,	O
3	3	CD	O
,	,	,	O
3-hexafluoro-2-propanol	3-hexafluoro-2-propanol	CD	O
and	and	CC	O
Thioflavin	Thioflavin	NNP	O
T	T	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
TCI	TCI	NNP	O
Development	Development	NNP	O
.	.	.	O

Î²-Amyloid1	Î²-Amyloid1	NNP	O
-	-	HYPH	O
42	42	CD	O
,	,	,	O
supplied	supply	VBN	O
as	as	IN	O
trifluoroacetate	trifluoroacetate	NN	O
salt	salt	NN	O
,	,	,	O
and	and	CC	O
eeAChE	eeAChE	NNP	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Royobiotech	Royobiotech	NNP	O
Co.	Co.	NNP	O
,	,	,	O
Ltd	Ltd	NNP	O
and	and	CC	O
Sigma	Sigma	NNP	O
-	-	HYPH	O
Aldrich	Aldrich	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

For	for	IN	O
co	co	NN	O
-	-	NN	O
incubation	incubation	JJ	O
experiments	experiment	NNS	O
,	,	,	O
aliquots	aliquot	NNS	O
of	of	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
peptide	peptide	NN	O
and	and	CC	O
AChE	AChE	``	O
in	in	IN	O
presence	presence	NN	O
or	or	CC	O
absence	absence	NN	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compounds	compound	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
for	for	IN	O
48âh	48âh	CD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
final	final	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
dissolved	dissolve	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
and	and	CC	O
diluted	diluted	JJ	O
0.215âM	0.215âm	CD	O
sodium	sodium	NN	O
phosphate	phosphate	NN	O
buffer	buffer	NN	O
,	,	,	O
pH	pH	NNP	O
8.0	8.0	CD	O
,	,	,	O
AChE	AChE	''	O
dissolved	dissolve	VBN	O
in	in	IN	O
0.215âM	0.215âm	CD	O
sodium	sodium	NN	O
phosphate	phosphate	NN	O
buffer	buffer	NN	O
,	,	,	O
pH	pH	NNP	O
8.0	8.0	CD	O
and	and	CC	O
test	test	NN	O
compounds	compound	NNS	O
were	be	VBD	O
200âÎ¼M	200âî¼m	CD	O
,	,	,	O
2âÎ¼M	2âî¼m	CD	O
and	and	CC	O
100âÎ¼M	100âî¼m	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

After	after	IN	O
co	co	NN	O
-	-	NN	O
incubation	incubation	NN	O
,	,	,	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
5âÎ¼M	5âî¼m	CD	O
ThT	tht	NN	O
in	in	IN	O
50âmM	50âmm	CD	O
glycine	glycine	JJ	O
-	-	HYPH	O
NaOH	naoh	NN	O
buffer	buffer	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
fluorescence	fluorescence	NN	O
was	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
multi	multi	JJ	O
-	-	JJ	O
mode	mode	JJ	O
plate	plate	NN	O
reader	reader	NN	O
at	at	IN	O
Î»ex	Î»ex	NNP	O
=	=	SYM	O
446ânm	446ânm	CD	O
and	and	CC	O
Î»em	î»em	UH	O
=	=	SYM	O
490ânm	490ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
percent	percent	NN	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
AChE	ache	RBS	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
inhibitor	inhibitor	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
following	follow	VBG	O
formula	formula	NN	O
:	:	:	O
100	100	CD	O
â	â	NNPS	O
,	,	,	O
where	where	WRB	O
IFi	IFi	NNS	O
and	and	CC	O
IFo	IFo	NNS	O
are	be	VBP	O
the	the	DT	O
fluorescence	fluorescence	NN	O
intensities	intensity	NNS	O
obtained	obtain	VBN	O
for	for	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
and	and	CC	O
in	in	IN	O
the	the	DT	O
absence	absence	NN	O
of	of	IN	O
inhibitor	inhibitor	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Each	each	DT	O
assay	assay	NN	O
was	be	VBD	O
run	run	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
and	and	CC	O
each	each	DT	O
reaction	reaction	NN	O
was	be	VBD	O
repeated	repeat	VBN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
independent	independent	JJ	O
times	time	NNS	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
compounds	compound	NNS	O
4c	4c	NNP	O
-	-	HYPH	O
f	f	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
on	on	IN	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
were	be	VBD	O
also	also	RB	O
measured	measure	VBN	O
by	by	IN	O
the	the	DT	O
ThT	ThT	NNP	O
assay	assay	NN	B
.	.	.	O

HFIP	HFIP	NNS	O
and	and	CC	O
ThT	ThT	NNP	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
TCI	TCI	NNP	O
Development	Development	NNP	O
.	.	.	O

AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Royobiotech	Royobiotech	NNP	O
Co.	Co.	NNP	O
,	,	,	O
Ltd	Ltd	NNP	O
.	.	.	O

The	the	DT	O
monomeric	monomeric	JJ	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
samples	sample	NNS	O
were	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
HFIP	HFIP	NNS	O
and	and	CC	O
diluted	dilute	VBN	O
with	with	IN	O
a	a	DT	O
50âmM	50âmm	CD	O
phosphate	phosphate	NN	O
buffer	buffer	NN	O
to	to	TO	O
give	give	VB	O
a	a	DT	O
25âÎ¼M	25âî¼m	CD	O
solution	solution	NN	O
.	.	.	O

The	the	DT	O
test	test	NN	O
compound	compound	NN	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
DMSO	DMSO	NNP	O
250âÎ¼M	250âî¼m	CD	O
for	for	IN	O
storage	storage	NN	O
and	and	CC	O
needed	need	VBD	O
not	not	RB	O
to	to	TO	O
be	be	VB	O
diluted	dilute	VBN	O
prior	prior	RB	O
to	to	IN	O
use	use	NN	O
.	.	.	O

In	in	IN	O
each	each	DT	O
well	well	RB	O
,	,	,	O
1âÎ¼L	1âî¼l	CD	O
of	of	IN	O
test	test	NN	O
compound	compound	NN	O
at	at	IN	O
final	final	JJ	O
concentration	concentration	NN	O
of	of	IN	O
25âÎ¼M	25âî¼m	CD	O
and	and	CC	O
9âÎ¼L	9âî¼l	CD	O
of	of	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
sample	sample	NN	O
were	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
obtained	obtained	JJ	O
mixture	mixture	NN	O
was	be	VBD	O
incubated	incubate	VBN	O
in	in	IN	O
dark	dark	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
46â48âh	46â48âh	CD	O
with	with	IN	O
no	no	DT	O
agitation	agitation	NN	O
.	.	.	O

Then	then	RB	O
,	,	,	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
5âÎ¼M	5âî¼m	CD	O
ThT	tht	NN	O
in	in	IN	O
50âmM	50âmm	CD	O
glycine	glycine	JJ	O
-	-	HYPH	O
NaOH	naoh	NN	O
buffer	buffer	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
percent	percent	NN	O
inhibition	inhibition	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
method	method	NN	O
same	same	JJ	O
as	as	IN	O
that	that	DT	O
of	of	IN	O
AChE	AChE	``	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1â42	aî²1â42	NN	O
experiment	experiment	NN	O
.	.	.	O

The	the	DT	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
test	test	NN	O
compound	compound	NN	O
on	on	IN	O
the	the	DT	O
human	human	JJ	O
neuroblastoma	neuroblastoma	NN	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
cells	cell	NNS	O
was	be	VBD	O
evaluated	evaluate	VBN	O
by	by	IN	O
MTT	MTT	NNP	O
assay	assay	NN	B
.	.	.	O

The	the	DT	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
cells	cell	NNS	O
were	be	VBD	O
grown	grow	VBN	O
in	in	IN	O
a	a	DT	O
1:1	1:1	CD	O
mixture	mixture	NN	O
of	of	IN	O
Eagle	Eagle	NNP	O
's	's	POS	O
minimum	minimum	JJ	O
essential	essential	JJ	O
medium	medium	NN	O
and	and	CC	O
ham	ham	NNP	O
's	's	POS	O
F-12	f-12	CD	O
medium	medium	NN	O
supplemented	supplement	VBN	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
foetal	foetal	JJ	O
bovine	bovine	NN	O
serum	serum	NN	O
,	,	,	O
100âU	100âU	NNP	O
/	/	SYM	O
mL	mL	NNP	O
penicillin	penicillin	NN	O
and	and	CC	O
100âmg	100âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
streptomycin	streptomycin	NNP	O
in	in	IN	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

For	for	IN	O
assay	assay	NN	O
,	,	,	O
cells	cell	NNS	O
were	be	VBD	O
seeded	seed	VBN	O
into	into	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
at	at	IN	O
a	a	DT	O
density	density	NN	O
of	of	IN	O
10000	10000	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	RB	O
and	and	CC	O
treated	treat	VBN	O
with	with	IN	O
compound	compound	NN	O
4c	4c	CD	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

After	after	IN	O
this	this	DT	O
treatment	treatment	NN	O
,	,	,	O
20âÎ¼L	20âî¼l	CD	O
of	of	IN	O
MTT	MTT	NNP	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

Four	four	CD	O
hours	hour	NNS	O
later	later	RB	O
,	,	,	O
the	the	DT	O
medium	medium	NN	O
was	be	VBD	O
removed	remove	VBN	O
,	,	,	O
and	and	CC	O
200âÎ¼L	200âî¼l	CD	O
of	of	IN	O
DMSO	DMSO	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
dissolve	dissolve	VB	O
the	the	DT	O
formazan	formazan	NNP	O
crystal	crystal	NN	O
formed	form	VBN	O
.	.	.	O

The	the	DT	O
absorbance	absorbance	NN	O
was	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
a	a	DT	O
microculture	microculture	JJ	O
plate	plate	NN	O
reader	reader	NN	O
with	with	IN	O
a	a	DT	O
test	test	NN	O
wavelength	wavelength	NN	O
of	of	IN	O
570ânm	570ânm	CD	O
and	and	CC	O
a	a	DT	O
reference	reference	NN	O
wavelength	wavelength	NN	O
of	of	IN	O
630ânm	630ânm	CD	O
.	.	.	O

Results	result	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
the	the	DT	O
meanâÂ±âSD	meanâÂ±âSD	NNP	O
of	of	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

A	a	DT	O
total	total	NN	O
of	of	IN	O
40	40	CD	O
Kunming	Kunming	NNP	O
mice	mouse	NNS	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
acute	acute	JJ	O
toxicity	toxicity	NN	O
of	of	IN	O
compound	compound	NN	O
4c	4c	CD	B
,	,	,	B
.	.	.	O

All	all	DT	O
mice	mouse	NNS	O
weighting	weight	VBG	O
18â25âg	18â25âg	CD	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Hunan	Hunan	NNP	O
SJA	SJA	NNP	O
Laboratory	Laboratory	NNP	O
Animal	Animal	NNP	O
Co.	Co.	NNP	O
,	,	,	O
Ltd.	Ltd.	NNP	O
and	and	CC	O
randomly	randomly	RB	O
divided	divide	VBN	O
into	into	IN	O
corresponding	corresponding	JJ	O
groups	group	NNS	O
.	.	.	O

They	-PRON-	PRP	O
were	be	VBD	O
maintained	maintain	VBN	O
under	under	IN	O
a	a	DT	O
12âh	12âh	CD	O
light	light	JJ	O
/	/	SYM	O
dark	dark	JJ	O
cycle	cycle	NN	O
and	and	CC	O
allowed	allow	VBD	O
free	free	JJ	O
access	access	NN	O
to	to	TO	O
tap	tap	VB	O
water	water	NN	O
and	and	CC	O
standard	standard	JJ	O
laboratory	laboratory	NN	O
chow	chow	NN	O
.	.	.	O

The	the	DT	O
room	room	NN	O
was	be	VBD	O
maintained	maintain	VBN	O
at	at	IN	O
temperature	temperature	NN	O
of	of	IN	O
23âÂ±â2âÂ	23ââ±â2ââ	CD	O
°	°	,	O
C	C	NNP	O
with	with	IN	O
a	a	DT	O
relative	relative	JJ	O
humidity	humidity	NN	O
of	of	IN	O
55âÂ±â5	55ââ±â5	CD	O
%	%	NN	O
.	.	.	O

Prior	prior	RB	O
to	to	IN	O
dosing	dose	VBG	O
,	,	,	O
all	all	DT	O
animals	animal	NNS	O
were	be	VBD	O
acclimated	acclimate	VBN	O
to	to	IN	O
this	this	DT	O
environment	environment	NN	O
for	for	IN	O
5âdays	5âdays	CD	O
.	.	.	O

Compound	Compound	NNP	O
4c	4c	NNP	O
was	be	VBD	O
suspended	suspend	VBN	O
in	in	IN	O
0.5	0.5	CD	O
%	%	NN	O
carboxymethyl	carboxymethyl	NN	O
cellulose	cellulose	NN	O
sodium	sodium	NN	O
salt	salt	NN	O
solution	solution	NN	O
and	and	CC	O
given	give	VBN	O
via	via	IN	O
oral	oral	JJ	O
administration	administration	NN	O
to	to	IN	O
the	the	DT	O
divided	divided	JJ	O
experimental	experimental	JJ	O
groups	group	NNS	O
0	0	CD	O
,	,	,	O
625	625	CD	O
,	,	,	O
1250	1250	CD	O
and	and	CC	O
2500âmg	2500âmg	NNPS	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
nâ=â10	nâ=â10	NN	O
per	per	IN	O
group	group	NN	O
.	.	.	O

After	after	IN	O
administration	administration	NN	O
,	,	,	O
animals	animal	NNS	O
were	be	VBD	O
observed	observe	VBN	O
continuously	continuously	RB	O
for	for	IN	O
the	the	DT	O
first	first	JJ	O
4âh	4âh	CD	O
for	for	IN	O
any	any	DT	O
abnormal	abnormal	JJ	O
behavioural	behavioural	JJ	O
changes	change	NNS	O
or	or	CC	O
deaths	death	NNS	O
,	,	,	O
then	then	RB	O
intermittently	intermittently	RB	O
for	for	IN	O
the	the	DT	O
next	next	JJ	O
24âh	24âh	CD	O
,	,	,	O
and	and	CC	O
occasionally	occasionally	RB	O
thereafter	thereafter	RB	O
for	for	IN	O
14âdays	14âdays	CD	O
for	for	IN	O
the	the	DT	O
onset	onset	NN	O
of	of	IN	O
any	any	DT	O
delayed	delay	VBN	O
effects	effect	NNS	O
.	.	.	O

On	on	IN	O
the	the	DT	O
14th	14th	JJ	O
day	day	NN	O
,	,	,	O
all	all	DT	O
mice	mouse	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
after	after	IN	O
being	be	VBG	O
anaesthetized	anaesthetize	VBN	O
by	by	IN	O
ether	ether	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
possible	possible	JJ	O
toxic	toxic	JJ	O
damage	damage	NN	O
to	to	IN	O
liver	liver	NN	O
,	,	,	O
heart	heart	NN	O
and	and	CC	O
kidneys	kidney	NNS	O
was	be	VBD	O
examined	examine	VBN	O
macroscopically	macroscopically	RB	O
.	.	.	O

The	the	DT	O
synthetic	synthetic	JJ	O
pathways	pathway	NNS	O
of	of	IN	O
target	target	NN	O
derivatives	derivative	NNS	O
are	be	VBP	O
illustrated	illustrate	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
1	1	CD	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
the	the	DT	O
previously	previously	RB	O
reported	report	VBN	O
methods	method	NNS	O
,	,	,	O
the	the	DT	O
2-quinolinone	2-quinolinone	CD	O
cores	core	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
through	through	IN	O
different	different	JJ	O
procedures	procedure	NNS	O
and	and	CC	O
starting	start	VBG	O
materials	material	NNS	B
,	,	,	B
,	,	,	B
.	.	.	O

The	the	DT	O
compound	compound	NN	O
2	2	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
from	from	IN	O
the	the	DT	O
condensation	condensation	NN	O
of	of	IN	O
trans	trans	JJ	O
-	-	JJ	O
cinnamic	cinnamic	JJ	O
acid	acid	NN	O
chloride	chloride	NN	O
with	with	IN	O
m	m	NNP	O
-	-	HYPH	O
anisidine	anisidine	NNP	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
an	an	DT	O
intramolecular	intramolecular	NN	O
Friedel	Friedel	NNP	O
-	-	HYPH	O
Crafts	Crafts	NNP	O
acylation	acylation	NN	O
/	/	SYM	O
dearylation	dearylation	NN	O
reaction	reaction	NN	O
in	in	IN	O
refluxing	refluxe	VBG	O
chlorobenzene	chlorobenzene	NN	O
with	with	IN	O
aluminium	aluminium	NN	O
chloride	chloride	NN	O
as	as	IN	O
Lewis	Lewis	NNP	O
acid	acid	NN	O
,	,	,	O
while	while	IN	O
the	the	DT	O
compounds	compound	NNS	O
7a	7a	NNP	O
-	-	HYPH	O
b	b	NNP	O
were	be	VBD	O
prepared	prepare	VBN	O
from	from	IN	O
m	m	NN	O
-	-	HYPH	O
phenylenediamine	phenylenediamine	NN	O
and	and	CC	O
ethyl	ethyl	NNP	O
acetoacetate	acetoacetate	NNP	O
/	/	SYM	O
ethyl	ethyl	NN	O
2-methylacetoacetate	2-methylacetoacetate	CD	O
by	by	IN	O
three	three	CD	O
steps	step	NNS	O
including	include	VBG	O
Pechmann	Pechmann	NNP	O
condensation	condensation	NN	O
reaction	reaction	NN	O
,	,	,	O
diazotisation	diazotisation	NN	O
,	,	,	O
and	and	CC	O
hydrolysis	hydrolysis	NN	O
.	.	.	O

When	when	WRB	O
these	these	DT	O
key	key	JJ	O
intermediates	intermediate	NNS	O
were	be	VBD	O
finished	finish	VBN	O
,	,	,	O
they	-PRON-	PRP	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
corresponding	correspond	VBG	O
É	é	NN	O
,	,	,	O
Ï-dibromoalkanes	ï-dibromoalkane	VBZ	O
to	to	TO	O
provide	provide	VB	O
compounds	compound	NNS	O
3a	3a	NNP	O
-	-	HYPH	O
e	e	NNP	O
and	and	CC	O
8a	8a	NNP	O
-	-	HYPH	O
b	b	NNP	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
reacting	react	VBG	O
compounds	compound	NNS	O
3a	3a	NNP	O
-	-	HYPH	O
e	e	NNP	O
and	and	CC	O
8a	8a	NNP	O
-	-	HYPH	O
b	b	NNP	O
with	with	IN	O
the	the	DT	O
appropriate	appropriate	JJ	O
secondary	secondary	JJ	O
amines	amine	NNS	O
,	,	,	O
carbon	carbon	NN	O
disulphide	disulphide	NN	O
and	and	CC	O
TEA	TEA	NNP	O
in	in	IN	O
DMF	DMF	NNP	O
afforded	afford	VBD	O
the	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
4a	4a	NNP	O
-	-	HYPH	O
m	m	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
compounds	compound	NNS	O
4a	4a	NNP	O
-	-	HYPH	O
m	m	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
cinnamoyl	cinnamoyl	NN	O
chloride	chloride	NN	O
,	,	,	O
dry	dry	JJ	O
dichloromethane	dichloromethane	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
reflux	reflux	NN	O
;	;	:	O
AlCl3	AlCl3	NNP	O
,	,	,	O
chlorobenzene	chlorobenzene	NNP	O
,	,	,	O
8âh	8âh	CD	O
,	,	,	O
reflux	reflux	NN	O
;	;	:	O
Î±	î±	NN	O
,	,	,	O
Ï-dibromoalkanes	Ï-dibromoalkanes	NNP	O
,	,	,	O
K2CO3	K2CO3	NNP	O
,	,	,	O
acetone	acetone	NN	O
,	,	,	O
reflux	reflux	NNP	O
,	,	,	O
4âh	4âh	CD	O
;	;	:	O
appropriate	appropriate	JJ	O
secondary	secondary	JJ	O
amines	amine	NNS	O
,	,	,	O
CS2	CS2	NNP	O
,	,	,	O
TEA	TEA	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
r.t	r.t	NNP	O
.	.	NNP	O

,	,	,	O
12âh	12âh	CD	O
.	.	.	O

ethyl	ethyl	NNP	O
acetoacetate	acetoacetate	NN	O
for	for	IN	O
6a	6a	NNP	O
,	,	,	O
ethyl	ethyl	NN	O
2-methylacetoacetate	2-methylacetoacetate	CD	O
for	for	IN	O
6âb	6âb	CD	O
,	,	,	O
150âÂ	150ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
48âh	48âh	CD	O
;	;	:	O
NaNO2	NaNO2	NNP	O
,	,	,	O
H2SO4	H2SO4	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
10âM	10âM	NNP	O
,	,	,	O
H2SO4	H2SO4	NNP	O
,	,	,	O
reflux	reflux	NN	O
,	,	,	O
10âmin	10âmin	CD	O
.	.	.	O

The	the	DT	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
target	target	NN	O
compounds	compound	NNS	O
4a	4a	NNP	O
-	-	HYPH	O
m	m	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
against	against	IN	O
eeAChE	eeAChE	NNP	O
and	and	CC	O
eqBuChE	eqBuChE	NNS	O
were	be	VBD	O
determined	determine	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
spectrophotometric	spectrophotometric	JJ	O
method	method	NN	O
described	describe	VBN	O
by	by	IN	O
Ellman	Ellman	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	B
.	.	.	O

For	for	IN	O
comparison	comparison	NN	O
purposes	purpose	NNS	O
,	,	,	O
three	three	CD	O
well	well	RB	O
-	-	HYPH	O
known	know	VBN	O
cholinesterase	cholinesterase	NN	O
inhibitors	inhibitor	NNS	O
,	,	,	O
donepezil	donepezil	NNP	O
,	,	,	O
galanthamine	galanthamine	NN	O
and	and	CC	O
tacrine	tacrine	JJ	O
,	,	,	O
were	be	VBD	O
used	use	VBN	O
as	as	IN	O
reference	reference	NN	O
compounds	compound	NNS	O
.	.	.	O

The	the	DT	O
experimental	experimental	JJ	O
results	result	NNS	O
were	be	VBD	O
presented	present	VBN	O
as	as	IN	O
IC50	IC50	NNP	O
,	,	,	O
or	or	CC	O
for	for	IN	O
poorly	poorly	RB	O
active	active	JJ	O
compounds	compound	NNS	O
,	,	,	O
as	as	IN	O
the	the	DT	O
percentage	percentage	NN	O
of	of	IN	O
inhibition	inhibition	NN	O
at	at	IN	O
10âÎ¼M.	10âî¼m.	CD	O
All	all	PDT	O
these	these	DT	O
results	result	NNS	O
are	be	VBP	O
summarised	summarise	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

It	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
seen	see	VBN	O
from	from	IN	O
the	the	DT	O
table	table	NN	O
that	that	IN	O
most	most	JJS	O
of	of	IN	O
compounds	compound	NNS	O
show	show	VBP	O
moderate	moderate	JJ	O
to	to	IN	O
good	good	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
AChE	AChE	''	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
ranging	range	VBG	O
from	from	IN	O
micromolar	micromolar	JJ	O
to	to	IN	O
sub	sub	JJ	O
-	-	JJ	O
micromolar	micromolar	JJ	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
compound	compound	NNP	O
4c	4c	NNP	O
displayed	display	VBD	O
the	the	DT	O
highest	high	JJS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
to	to	IN	O
AChE	AChE	''	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
0.22âÎ¼M	0.22âÎ¼M	NNP	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
similar	similar	JJ	O
to	to	IN	O
that	that	DT	O
of	of	IN	O
tacrine	tacrine	JJ	O
IC50	IC50	NNP	O
=	=	SYM	O
0.21âÎ¼M	0.21âÎ¼M	NNP	O
and	and	CC	O
7.5	7.5	CD	O
times	time	NNS	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
galanthamine	galanthamine	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
1.65âÎ¼M	1.65âÎ¼M	NNP	O
.	.	.	O

With	with	IN	O
exception	exception	NN	O
of	of	IN	O
compound	compound	NN	O
4âh	4âh	CD	O
,	,	,	O
no	no	DT	O
significant	significant	JJ	O
BuChE	BuChE	NNP	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
was	be	VBD	O
observed	observe	VBN	O
for	for	IN	O
the	the	DT	O
present	present	JJ	O
compounds	compound	NNS	O
.	.	.	O

Considering	consider	VBG	O
inhibition	inhibition	NN	O
of	of	IN	O
BuChE	BuChE	NNP	O
may	may	MD	O
lead	lead	VB	O
to	to	IN	O
unexpected	unexpected	JJ	O
side	side	NN	O
effects	effect	NNS	O
in	in	IN	O
the	the	DT	O
peripheral	peripheral	JJ	O
tissues	tissue	NNS	O
,	,	,	O
these	these	DT	O
compounds	compound	NNS	O
will	will	MD	O
be	be	VB	O
more	more	RBR	O
beneficial	beneficial	JJ	O
for	for	IN	O
AD	ad	NN	O
treatment	treatment	NN	O
.	.	.	O

Inhibition	inhibition	NN	O
of	of	IN	O
eeAChE	eeAChE	NNP	O
and	and	CC	O
eqBuChE	eqbuche	FW	O
by	by	IN	O
compounds	compound	NNS	O
4a	4a	NNP	O
-	-	HYPH	O
m	m	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b.aThe	b.athe	NN	O
50	50	CD	O
%	%	NN	O
inhibitory	inhibitory	JJ	O
concentration	concentration	NN	O
of	of	IN	O
eeAChE	eeAChE	NNP	O
or	or	CC	O
percent	percent	NN	O
inhibition	inhibition	NN	O
with	with	IN	O
inhibitor	inhibitor	NN	O
at	at	IN	O
10âÎ¼M	10âî¼m	CD	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
of	of	IN	O
three	three	CD	O
experiments).bThe	experiments).bThe	NNP	O
50	50	CD	O
%	%	NN	O
inhibitory	inhibitory	JJ	O
concentration	concentration	NN	O
of	of	IN	O
eqBuChE	eqbuche	NN	O
or	or	CC	O
percent	percent	NN	O
inhibition	inhibition	NN	O
with	with	IN	O
inhibitor	inhibitor	NN	O
at	at	IN	O
10âÎ¼M	10âî¼m	CD	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
of	of	IN	O
three	three	CD	O
experiments	experiment	NNS	O
.	.	.	O

The	the	DT	O
previous	previous	JJ	O
studies	study	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
the	the	DT	O
linker	linker	NN	O
length	length	NN	O
between	between	IN	O
PAS	PAS	NNP	O
and	and	CC	O
CAS	CAS	NNP	O
binding	bind	VBG	O
moieties	moiety	NNS	O
played	play	VBD	O
a	a	DT	O
crucial	crucial	JJ	O
role	role	NN	O
in	in	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
optimal	optimal	JJ	O
length	length	NN	O
for	for	IN	O
the	the	DT	O
present	present	JJ	O
compounds	compound	NNS	O
,	,	,	O
compounds	compound	VBZ	O
4a	4a	NNP	O
-	-	HYPH	O
e	e	NNP	O
with	with	IN	O
different	different	JJ	O
linker	linker	NN	O
lengths	length	NNS	O
nâ=â2â6	nâ=â2â6	NNP	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
the	the	DT	O
initial	initial	JJ	O
step	step	NN	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
the	the	DT	O
table	table	NN	O
,	,	,	O
the	the	DT	O
inhibitory	inhibitory	NN	O
activities	activity	NNS	O
for	for	IN	O
AChE	AChE	``	O
changed	change	VBN	O
significantly	significantly	RB	O
as	as	IN	O
the	the	DT	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
was	be	VBD	O
varied	varied	JJ	O
.	.	.	O

From	from	IN	O
the	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
,	,	,	O
compound	compound	NNP	O
4c	4c	NNP	O
containing	contain	VBG	O
a	a	DT	O
four	four	CD	O
-	-	HYPH	O
carbon	carbon	NN	O
atom	atom	NN	O
linker	linker	NN	O
showed	show	VBD	O
better	well	JJR	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
than	than	IN	O
the	the	DT	O
other	other	JJ	O
compounds	compound	NNS	O
,	,	,	O
which	which	WDT	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
suitable	suitable	JJ	O
linker	linker	NN	O
length	length	NN	O
between	between	IN	O
the	the	DT	O
two	two	CD	O
anchoring	anchor	VBG	O
groups	group	NNS	O
for	for	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
was	be	VBD	O
four	four	CD	O
carbon	carbon	NN	O
atoms	atom	NNS	O
.	.	.	O

With	with	IN	O
the	the	DT	O
optimal	optimal	JJ	O
length	length	NN	O
in	in	IN	O
hand	hand	NN	O
,	,	,	O
different	different	JJ	O
terminal	terminal	JJ	O
amine	amine	NN	O
groups	group	NNS	O
were	be	VBD	O
introduced	introduce	VBN	O
to	to	TO	O
investigate	investigate	VB	O
their	-PRON-	PRP$	O
possible	possible	JJ	O
influences	influence	NNS	O
on	on	IN	O
AChE	ache	CD	O
inhibition	inhibition	NN	O
.	.	.	O

The	the	DT	O
no	no	DT	O
substituted	substituted	JJ	O
piperidine	piperidine	NN	O
moiety	moiety	NNP	O
seemed	seem	VBD	O
to	to	TO	O
be	be	VB	O
essential	essential	JJ	O
for	for	IN	O
AChE	AChE	``	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

Compound	Compound	NNP	O
4f	4f	NNS	O
IC50	IC50	NNP	O
=	=	SYM	O
0.69âÎ¼M	0.69âî¼m	NN	O
bearing	bear	VBG	O
a	a	DT	O
4-methyl	4-methyl	CD	O
group	group	NN	O
on	on	IN	O
the	the	DT	O
piperidine	piperidine	NN	O
ring	ring	NN	O
showed	show	VBD	O
3-fold	3-fold	CD	O
less	less	JJR	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
than	than	IN	O
the	the	DT	O
no	no	DT	O
substituted	substituted	JJ	O
compound	compound	NN	O
4c	4c	NNS	O
IC50	IC50	NNP	O
=	=	SYM	O
0.22âÎ¼M	0.22âÎ¼M	NNP	O
.	.	.	O

Replacement	replacement	NN	O
of	of	IN	O
the	the	DT	O
methyl	methyl	NN	O
group	group	NN	O
with	with	IN	O
an	an	DT	O
isopropyl	isopropyl	NN	O
group	group	NN	O
led	lead	VBD	O
to	to	IN	O
a	a	DT	O
largely	largely	RB	O
drop	drop	NN	O
in	in	IN	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
.	.	.	O

Compound	compound	NN	O
4âg	4âg	CD	O
IC50	IC50	NNP	O
=	=	SYM	O
9.61âÎ¼M	9.61âî¼m	NN	O
only	only	RB	O
gave	give	VBD	O
a	a	DT	O
micromolar	micromolar	JJ	O
inhibition	inhibition	NN	O
to	to	IN	O
AChE.	ache.	VB	O
However	however	RB	O
,	,	,	O
it	-PRON-	PRP	O
should	should	MD	O
be	be	VB	O
noted	note	VBN	O
that	that	IN	O
introduction	introduction	NN	O
of	of	IN	O
another	another	DT	O
piperidine	piperidine	NN	O
to	to	IN	O
4-postion	4-postion	CD	O
of	of	IN	O
piperidine	piperidine	NN	O
ring	ring	NN	O
resulted	result	VBD	O
in	in	IN	O
a	a	DT	O
significant	significant	JJ	O
improvement	improvement	NN	O
in	in	IN	O
BuChE	buche	NN	O
inhibition	inhibition	NN	O
.	.	.	O

Compound	compound	NN	O
4âh	4âh	CD	O
IC50	IC50	NNP	O
=	=	SYM	O
3.80âÎ¼M	3.80âî¼m	NN	O
for	for	IN	O
AChE	AChE	''	O
;	;	:	O
IC50	IC50	NNP	O
=	=	SYM	O
2.00âÎ¼M	2.00âî¼m	CD	O
for	for	IN	O
BuChE	BuChE	NNP	O
was	be	VBD	O
the	the	DT	O
only	only	JJ	O
compound	compound	NN	O
with	with	IN	O
BuChE	buche	NN	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
in	in	IN	O
this	this	DT	O
series	series	NN	O
.	.	.	O

Installation	installation	NN	O
of	of	IN	O
a	a	DT	O
hydroxy	hydroxy	NN	O
group	group	NN	O
on	on	IN	O
piperidine	piperidine	NNP	O
ring	ring	NN	O
was	be	VBD	O
not	not	RB	O
tolerated	tolerate	VBN	O
,	,	,	O
as	as	IN	O
compounds	compound	NNS	O
4i	4i	NNP	O
and	and	CC	O
4j	4j	NNP	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
any	any	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
AChE.	ache.	NN	O
Besides	besides	IN	O
,	,	,	O
replacement	replacement	NN	O
of	of	IN	O
the	the	DT	O
piperidine	piperidine	NN	O
group	group	NN	O
with	with	IN	O
other	other	JJ	O
cyclic	cyclic	JJ	O
amines	amine	NNS	O
were	be	VBD	O
also	also	RB	O
not	not	RB	O
beneficial	beneficial	JJ	O
for	for	IN	O
the	the	DT	O
AChE	AChE	``	O
inhibition	inhibition	NN	O
.	.	.	O

Compounds	compound	NNS	O
4k	4k	NNP	O
and	and	CC	O
4âl	4âl	CD	O
,	,	,	O
possessing	possess	VBG	O
a	a	DT	O
4-methylpiperazine	4-methylpiperazine	CD	O
moiety	moiety	NN	O
and	and	CC	O
a	a	DT	O
morpholinyl	morpholinyl	JJ	O
moiety	moiety	NN	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
displayed	display	VBD	O
neglected	neglected	JJ	O
inhibition	inhibition	NN	O
on	on	IN	O
AChE.	ache.	NN	O
Unlike	unlike	IN	O
our	-PRON-	PRP$	O
previous	previous	JJ	O
study	study	NN	O
that	that	DT	O
contraction	contraction	NN	O
of	of	IN	O
the	the	DT	O
piperidine	piperidine	NN	O
ring	ring	NN	O
to	to	IN	O
pyrrole	pyrrole	NNP	O
ring	ring	NN	O
had	have	VBD	O
little	little	JJ	O
impact	impact	NN	O
on	on	IN	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	B
,	,	,	O
in	in	IN	O
present	present	JJ	O
work	work	NN	O
compound	compound	NN	O
4âm	4âm	CD	O
showed	show	VBD	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
less	less	JJR	O
than	than	IN	O
50	50	CD	O
%	%	NN	O
at	at	IN	O
10âÎ¼M.	10âî¼m.	CD	O
Moreover	moreover	RB	O
,	,	,	O
compound	compound	NN	O
9a	9a	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
0.30âÎ¼M	0.30âî¼m	NN	O
with	with	IN	O
mono	mono	NNP	O
-	-	HYPH	O
methyl	methyl	NNP	O
group	group	NN	O
and	and	CC	O
compound	compound	NNP	O
9b	9b	NNS	O
IC50	IC50	NNP	O
=	=	SYM	O
0.34âÎ¼M	0.34âÎ¼M	NNP	O
with	with	IN	O
dimethyl	dimethyl	JJ	O
groups	group	NNS	O
on	on	IN	O
coumarin	coumarin	NNP	O
ring	ring	NN	O
were	be	VBD	O
also	also	RB	O
synthesised	synthesise	VBN	O
to	to	TO	O
further	further	RB	O
extend	extend	VB	O
the	the	DT	O
SARs	sar	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
introduction	introduction	NN	O
of	of	IN	O
methyl	methyl	NN	O
group	group	NN	O
to	to	TO	O
coumarin	coumarin	VB	O
slightly	slightly	RB	O
reduced	reduce	VBD	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
AChE	AChE	NNP	O
in	in	IN	O
comparison	comparison	NN	O
to	to	IN	O
their	-PRON-	PRP$	O
analogue	analogue	NN	O
4c	4c	NN	O
.	.	.	O

The	the	DT	O
ability	ability	NN	O
to	to	TO	O
penetrate	penetrate	VB	O
the	the	DT	O
blood	blood	NN	O
-	-	HYPH	O
brain	brain	NN	O
barrier	barrier	NN	O
is	be	VBZ	O
the	the	DT	O
first	first	JJ	O
requirement	requirement	NN	O
for	for	IN	O
successful	successful	JJ	O
central	central	JJ	O
nervous	nervous	JJ	O
system	system	NN	O
drugs	drug	NNS	B
,	,	,	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
to	to	TO	O
determine	determine	VB	O
the	the	DT	O
BBB	BBB	NNP	O
penetration	penetration	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
present	present	JJ	O
compounds	compound	NNS	O
,	,	,	O
a	a	DT	O
parallel	parallel	JJ	O
artificial	artificial	JJ	O
membrane	membrane	NN	O
permeability	permeability	NN	O
assay	assay	NNP	O
was	be	VBD	O
performed	perform	VBN	O
.	.	.	O

This	this	DT	O
assay	assay	NN	O
was	be	VBD	O
established	establish	VBN	O
by	by	IN	O
Di	Di	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

and	and	CC	O
has	have	VBZ	O
been	be	VBN	O
successfully	successfully	RB	O
applied	apply	VBN	O
to	to	TO	O
predict	predict	VB	O
the	the	DT	O
passive	passive	JJ	O
BBB	BBB	NNP	O
permeation	permeation	NN	O
of	of	IN	O
a	a	DT	O
multitude	multitude	NN	O
of	of	IN	O
diverse	diverse	JJ	O
compounds	compound	NNS	B
.	.	.	O

After	after	IN	O
comparing	compare	VBG	O
experimental	experimental	JJ	O
permeabilities	permeability	NNS	O
with	with	IN	O
the	the	DT	O
reported	report	VBN	O
values	value	NNS	O
of	of	IN	O
9	9	CD	O
commercial	commercial	JJ	O
drugs	drug	NNS	O
,	,	,	O
a	a	DT	O
plot	plot	NN	O
of	of	IN	O
experiment	experiment	NN	O
data	datum	NNS	O
versus	versus	IN	O
the	the	DT	O
bibliographic	bibliographic	JJ	O
values	value	NNS	O
gave	give	VBD	O
a	a	DT	O
good	good	JJ	O
linear	linear	NN	O
correlation	correlation	NN	O
:	:	:	O
Pe	Pe	NNP	O
=	=	SYM	O
0.9082	0.9082	CD	O
Pe	Pe	NNS	O
â	â	NN	O
0.3034	0.3034	CD	O
.	.	.	O

From	from	IN	O
this	this	DT	O
equation	equation	NN	O
and	and	CC	O
considering	consider	VBG	O
the	the	DT	O
limit	limit	NN	O
established	establish	VBN	O
by	by	IN	O
Di	Di	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	NNP	O

for	for	IN	O
BBB	BBB	NNP	O
permeation	permeation	NN	O
,	,	,	O
we	-PRON-	PRP	O
determined	determine	VBD	O
that	that	IN	O
compounds	compound	NNS	O
with	with	IN	O
permeabilities	permeability	NNS	O
above	above	IN	O
3.33âÃâ10â6âcm	3.33âãâ10â6âcm	CD	O
sâ1	sâ1	NNS	O
could	could	MD	O
cross	cross	VB	O
the	the	DT	O
BBB	BBB	NNP	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
the	the	DT	O
Table	table	NN	O
3	3	CD	O
,	,	,	O
with	with	IN	O
exception	exception	NN	O
of	of	IN	O
compounds	compound	NNS	O
4i	4i	NNP	O
and	and	CC	O
4j	4j	NNP	O
,	,	,	O
all	all	DT	O
compounds	compound	NNS	O
showed	show	VBD	O
the	the	DT	O
Pe	Pe	NNP	O
value	value	NN	O
higher	high	JJR	O
than	than	IN	O
3.33	3.33	CD	O
,	,	,	O
which	which	WDT	O
suggested	suggest	VBD	O
that	that	IN	O
they	-PRON-	PRP	O
were	be	VBD	O
able	able	JJ	O
to	to	TO	O
cross	cross	VB	O
the	the	DT	O
BBB	BBB	NNP	O
and	and	CC	O
might	may	MD	O
reach	reach	VB	O
the	the	DT	O
biological	biological	JJ	O
targets	target	NNS	O
located	locate	VBN	O
in	in	IN	O
the	the	DT	O
CNS	CNS	NNP	O
.	.	.	O

Lineal	lineal	NN	O
correlation	correlation	NN	O
between	between	IN	O
experimental	experimental	JJ	O
and	and	CC	O
reported	report	VBD	O
permeability	permeability	NN	O
of	of	IN	O
commercial	commercial	JJ	O
drugs	drug	NNS	O
using	use	VBG	O
the	the	DT	O
PAMPA	PAMPA	NNP	O
-	-	HYPH	O
BBB	BBB	NNP	O
assay	assay	NN	O
.	.	.	O

Pe	Pe	NNP	O
=	=	SYM	O
0.9082Peâ	0.9082peâ	CD	O
0.3034	0.3034	CD	O
.	.	.	O

Permeability	permeability	NN	O
Pe(Ã10â6	Pe(Ã10â6	NNP	O
in	in	IN	O
the	the	DT	O
PAMPA	PAMPA	NNP	O
-	-	HYPH	O
BBB	BBB	NNP	O
assay	assay	NN	O
for	for	IN	O
9	9	CD	O
commercial	commercial	JJ	O
drugs	drug	NNS	O
in	in	IN	O
the	the	DT	O
experiment	experiment	NN	O
validation.aAdapted	validation.aadapte	VBN	O
from	from	IN	O
Di	Di	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	O

CYTOWANIE.bExperimental	cytowanie.bexperimental	JJ	O
data	datum	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
meanâÂ±âSD	meanââ±âsd	NN	O
from	from	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
,	,	,	O
using	use	VBG	O
PBS	PBS	NNP	O
:	:	:	O
EtOH	EtOH	NNP	O
as	as	IN	O
solvent	solvent	NN	O
.	.	.	O

Permeability	Permeability	NNP	O
Pe	Pe	NNP	O
Ã106âcm	Ã106âcm	.	O
/	/	SYM	O
s	s	NNPS	O
in	in	IN	O
the	the	DT	O
PAMPA	PAMPA	NNP	O
-	-	HYPH	O
BBB	BBB	NNP	O
assay	assay	NN	O
for	for	IN	O
target	target	NN	O
compounds	compound	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
predicted	predict	VBN	O
penetration	penetration	NN	O
into	into	IN	O
CNS.aPermeability	cns.apermeability	NN	O
Pe	Pe	NNP	O
Ã106âcm	Ã106âcm	.	O
/	/	SYM	O
s	s	NN	O
values	value	NNS	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
meanâÂ±âSD	meanââ±âsd	NN	O
from	from	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
,	,	,	O
using	use	VBG	O
PBS	PBS	NNP	O
:	:	:	O
EtOH	EtOH	NNP	O
as	as	IN	O
solvent.bCNSâ+	solvent.bCNSâ+	NNP	O
is	be	VBZ	O
predicted	predict	VBN	O
as	as	IN	O
high	high	JJ	O
BBB	BBB	NNP	O
permeation	permeation	NN	O
with	with	IN	O
Pe	Pe	NNP	O
Ã106âcm	Ã106âcm	.	O
/	/	SYM	O
s	s	NN	O
>	>	XX	O
3.33	3.33	CD	O
,	,	,	O
CNSâÂ±	CNSâÂ±	NNP	O
is	be	VBZ	O
uncertain	uncertain	JJ	O
for	for	IN	O
BBB	BBB	NNP	O
permeation	permeation	NN	O
with	with	IN	O
1.51â<âPe	1.51â<âpe	CD	O
Ã106âcm	Ã106âcm	NNS	O
/	/	SYM	O
s	s	NN	O
<	<	XX	O
3.33	3.33	CD	O
.	.	.	O

Since	since	IN	O
almost	almost	RB	O
all	all	DT	O
compounds	compound	NNS	O
could	could	MD	O
cross	cross	VB	O
the	the	DT	O
BBB	BBB	NNP	O
,	,	,	O
we	-PRON-	PRP	O
then	then	RB	O
selected	select	VBD	O
compounds	compound	VBZ	O
4c	4c	NNP	O
-	-	HYPH	O
f	f	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
with	with	IN	O
sub	sub	JJ	O
-	-	JJ	O
micromolar	micromolar	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
further	further	JJ	O
evaluation	evaluation	NN	O
on	on	IN	O
hAChE.	hache.	NN	O
As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Table	table	NN	O
4	4	CD	O
,	,	,	O
all	all	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
having	have	VBG	O
potent	potent	JJ	O
inhibition	inhibition	NN	O
on	on	IN	O
eeAChE	eeAChE	NNP	O
also	also	RB	O
exhibit	exhibit	VB	O
high	high	JJ	O
inhibition	inhibition	NN	O
to	to	TO	O
hAChE.	hache.	VB	O
It	-PRON-	PRP	O
is	be	VBZ	O
worth	worth	JJ	O
noting	note	VBG	O
that	that	IN	O
compounds	compound	NNS	O
4c	4c	NNP	O
,	,	,	O
4e	4e	NNP	O
and	and	CC	O
9b	9b	NN	O
did	do	VBD	O
not	not	RB	O
display	display	VB	O
better	well	JJR	O
activity	activity	NN	O
on	on	IN	O
eeAChE	eeAChE	NNP	O
than	than	IN	O
tacrine	tacrine	NN	O
but	but	CC	O
showed	show	VBD	O
stronger	strong	JJR	O
inhibition	inhibition	NN	O
on	on	IN	O
hAChE	hAChE	NNP	O
than	than	IN	O
tacrine	tacrine	JJ	O
,	,	,	O
especially	especially	RB	O
for	for	IN	O
compound	compound	NN	O
4c	4c	CD	O
IC50	IC50	NNP	O
=	=	SYM	O
0.16âÎ¼M	0.16âî¼m	NN	O
;	;	:	O
it	-PRON-	PRP	O
presented	present	VBD	O
nearly	nearly	RB	O
3-fold	3-fold	CD	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
hAChE	hAChE	NNP	O
than	than	IN	O
tacrine	tacrine	JJ	O
IC50	IC50	NNP	O
=	=	SYM	O
0.47âÎ¼M	0.47âÎ¼M	NNP	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
largely	largely	RB	O
improved	improve	VBN	O
in	in	IN	O
comparison	comparison	NN	O
to	to	IN	O
its	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
eeAChE.	eeAChE.	NNP	O
Inhibition	inhibition	NN	O
of	of	IN	O
hAChE	hache	NN	O
,	,	,	O
and	and	CC	O
AChE-	ache-	NN	O
and	and	CC	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
by	by	IN	O
selected	select	VBN	O
compounds.aThe	compounds.aThe	NNP	O
50	50	CD	O
%	%	NN	O
inhibitory	inhibitory	JJ	O
concentration	concentration	NN	O
of	of	IN	O
hAChE	hAChE	NNP	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
of	of	IN	O
three	three	CD	O
experiments).bInhibition	experiments).binhibition	NN	O
of	of	IN	O
AChE	ache	RBS	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1â42	aî²1â42	NN	O
aggregation	aggregation	NN	O
.	.	.	O

The	the	DT	O
thioflavin	thioflavin	JJ	O
-	-	HYPH	O
T	t	NN	O
fluorescence	fluorescence	NN	O
method	method	NN	O
was	be	VBD	O
used	use	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
the	the	DT	O
tested	test	VBN	O
inhibitor	inhibitor	NN	O
was	be	VBD	O
100âÎ¼M	100âî¼m	CD	O
meansâÂ±âSD	meansââ±âsd	CD	O
of	of	IN	O
three	three	CD	O
experiments).cInhibition	experiments).cInhibition	NNP	O
of	of	IN	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
.	.	.	O

The	the	DT	O
thioflavin	thioflavin	JJ	O
-	-	HYPH	O
T	t	NN	O
fluorescence	fluorescence	NN	O
method	method	NN	O
was	be	VBD	O
used	use	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
measurements	measurement	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
25âÎ¼M	25âî¼m	CD	O
inhibitor	inhibitor	NN	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
of	of	IN	O
three	three	CD	O
experiments	experiment	NNS	O
.	.	.	O

To	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
inhibition	inhibition	NN	O
mechanism	mechanism	NN	O
of	of	IN	O
present	present	JJ	O
compounds	compound	NNS	O
with	with	IN	O
AChE	AChE	``	O
,	,	,	O
compound	compound	NNP	O
4c	4c	CD	O
,	,	,	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
in	in	IN	O
this	this	DT	O
series	series	NN	O
,	,	,	O
was	be	VBD	O
taken	take	VBN	O
as	as	IN	O
a	a	DT	O
representative	representative	NN	O
for	for	IN	O
enzyme	enzyme	NNS	O
kinetic	kinetic	JJ	O
study	study	NN	O
.	.	.	O

It	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
seen	see	VBN	O
from	from	IN	O
the	the	DT	O
Lineweaver	Lineweaver	NNP	O
-	-	HYPH	O
Burk	Burk	NNP	O
plots	plot	NNS	O
Figure	figure	NN	O
3	3	CD	O
that	that	IN	O
both	both	DT	O
slopes	slope	NNS	O
and	and	CC	O
intercepts	intercept	NNS	O
are	be	VBP	O
increased	increase	VBN	O
as	as	IN	O
the	the	DT	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
inhibitor	inhibitor	NN	O
are	be	VBP	O
increased	increase	VBN	O
.	.	.	O

This	this	DT	O
pattern	pattern	NN	O
indicated	indicate	VBD	O
a	a	DT	O
mixed	mix	VBN	O
-	-	HYPH	O
type	type	NN	O
inhibition	inhibition	NN	O
,	,	,	O
which	which	WDT	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
present	present	JJ	O
compounds	compound	NNS	O
might	may	MD	O
be	be	VB	O
dual	dual	JJ	O
binding	bind	VBG	O
site	site	NN	O
inhibitors	inhibitor	NNS	O
,	,	,	O
being	be	VBG	O
able	able	JJ	O
to	to	TO	O
bind	bind	VB	O
simultaneously	simultaneously	RB	O
to	to	IN	O
the	the	DT	O
PAS	PAS	NNP	O
and	and	CC	O
CAS	CAS	NNP	O
of	of	IN	O
AChE.	AChE.	NNP	O
Replots	Replots	NNPS	O
of	of	IN	O
the	the	DT	O
slope	slope	NN	O
versus	versus	IN	O
concentration	concentration	NN	O
of	of	IN	O
4c	4c	CD	O
gave	give	VBD	O
an	an	DT	O
estimate	estimate	NN	O
of	of	IN	O
competitive	competitive	JJ	O
inhibition	inhibition	NN	O
constant	constant	JJ	O
,	,	,	O
Ki	Ki	NNP	O
,	,	,	O
of	of	IN	O
0.225âÎ¼M	0.225âÎ¼M	NNP	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

Kinetic	kinetic	JJ	O
study	study	NN	O
on	on	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
mechanism	mechanism	NN	O
of	of	IN	O
hAChE	hAChE	NNP	O
by	by	IN	O
compound	compound	NN	O
4c	4c	CD	O
.	.	.	O

Overlaid	Overlaid	NNP	O
Lineweaver	Lineweaver	NNP	O
-	-	HYPH	O
Burk	Burk	NNP	O
reciprocal	reciprocal	JJ	O
plots	plot	NNS	O
of	of	IN	O
hAChE	hache	NN	O
initial	initial	JJ	O
velocity	velocity	NN	O
at	at	IN	O
increasing	increase	VBG	O
substrate	substrate	JJ	O
concentrations	concentration	NNS	O
0.05â0.50âmM	0.05â0.50âmm	NN	O
in	in	IN	O
the	the	DT	O
absence	absence	NN	O
of	of	IN	O
inhibitor	inhibitor	NN	O
and	and	CC	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
0.4	0.4	CD	O
,	,	,	O
0.2	0.2	CD	O
and	and	CC	O
0.1âÎ¼M	0.1âî¼m	NN	O
of	of	IN	O
4c	4c	CD	O
are	be	VBP	O
shown	show	VBN	O
.	.	.	O

The	the	DT	O
plot	plot	NN	O
of	of	IN	O
the	the	DT	O
slopes	slope	NNS	O
of	of	IN	O
the	the	DT	O
Lineweaver	Lineweaver	NNP	O
-	-	HYPH	O
Burk	Burk	NNP	O
plots	plot	NNS	O
versus	versus	IN	O
inhibitor	inhibitor	NN	O
concentration	concentration	NN	O
.	.	.	O

To	to	TO	O
further	further	RB	O
determine	determine	VB	O
the	the	DT	O
interaction	interaction	NN	O
mode	mode	NN	O
of	of	IN	O
present	present	JJ	O
compounds	compound	NNS	O
with	with	IN	O
AChE	AChE	``	O
,	,	,	O
molecular	molecular	JJ	O
modelling	modelling	NN	O
studies	study	NNS	O
were	be	VBD	O
performed	perform	VBN	O
with	with	IN	O
a	a	DT	O
Molecular	Molecular	NNP	O
Operating	Operating	NNP	O
Environment	Environment	NNP	O
software	software	NN	O
.	.	.	O

The	the	DT	O
crystal	crystal	NN	O
structures	structure	NNS	O
of	of	IN	O
hAChE	hAChE	NNS	O
complexed	complexe	VBN	O
with	with	IN	O
donepezil	donepezil	NN	O
and	and	CC	O
TcAChE	tcache	NN	O
complexed	complexed	JJ	O
with	with	IN	O
bis	bis	JJ	O
-	-	HYPH	O
tacrine	tacrine	JJ	O
were	be	VBD	O
used	use	VBN	O
to	to	TO	O
establish	establish	VB	O
the	the	DT	O
starting	starting	NN	O
model	model	NN	O
.	.	.	O

Donepezil	Donepezil	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
a	a	DT	O
reference	reference	NN	O
compound	compound	NN	O
.	.	.	O

The	the	DT	O
docking	docking	NN	O
results	result	NNS	O
see	see	VB	O
Supporting	Supporting	NNP	O
Information	Information	NNP	O
,	,	,	O
Supplementary	Supplementary	NNP	O
Table	Table	NNP	O
S1âS2	S1âS2	NNP	O
indicated	indicate	VBD	O
that	that	IN	O
compounds	compound	VBZ	O
4c	4c	NNP	O
-	-	HYPH	O
f	f	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
with	with	IN	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
on	on	IN	O
both	both	CC	O
hAChE	hache	UH	O
and	and	CC	O
eeAChE	eeAChE	NNP	O
showed	show	VBD	O
lower	low	JJR	O
S	S	NNP	O
value	value	NN	O
than	than	IN	O
the	the	DT	O
other	other	JJ	O
compounds	compound	NNS	O
in	in	IN	O
corresponding	correspond	VBG	O
crystal	crystal	NN	O
structure	structure	NN	O
of	of	IN	O
AChE.	AChE.	NNP	O
Inspection	Inspection	NNP	O
of	of	IN	O
the	the	DT	O
docking	docking	NN	O
orientations	orientation	NNS	O
found	find	VBD	O
that	that	IN	O
most	most	JJS	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
exhibited	exhibit	VBD	O
the	the	DT	O
binding	bind	VBG	O
modes	mode	NNS	O
with	with	IN	O
hAChE	hAChE	NNP	O
and	and	CC	O
TcAChE	TcAChE	NNP	O
similar	similar	JJ	O
to	to	IN	O
those	those	DT	O
of	of	IN	O
donepezil	donepezil	NN	O
.	.	.	O

The	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
compound	compound	NN	O
4c	4c	NNPS	O
showed	show	VBD	O
the	the	DT	O
lowest	low	JJS	O
S	s	JJ	O
value	value	NN	O
on	on	IN	O
both	both	CC	O
hAChE	hache	NN	O
and	and	CC	O
TcAChE.	TcAChE.	NNP	O
As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
,	,	,	O
the	the	DT	O
interaction	interaction	NN	O
mode	mode	NN	O
of	of	IN	O
compound	compound	NN	O
4c	4c	CD	O
with	with	IN	O
hAChE	hAChE	NNS	O
indicate	indicate	VBP	O
that	that	IN	O
compound	compound	NN	O
4c	4c	NNP	O
fits	fit	VBZ	O
well	well	RB	O
into	into	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
hAChE	hache	NN	O
,	,	,	O
which	which	WDT	O
can	can	MD	O
occupy	occupy	VB	O
the	the	DT	O
entire	entire	JJ	O
enzymatic	enzymatic	JJ	O
CAS	cas	NN	O
,	,	,	O
mid	mid	JJ	O
-	-	NN	O
gorge	gorge	NN	O
site	site	NN	O
and	and	CC	O
PAS	PAS	NNP	O
.	.	.	O

The	the	DT	O
quinolinone	quinolinone	NN	O
moiety	moiety	NN	O
bound	bind	VBN	O
to	to	IN	O
the	the	DT	O
PAS	PAS	NNP	O
,	,	,	O
forming	form	VBG	O
a	a	DT	O
Ï-Ï	Ï-Ï	NNP	O
stacking	stack	VBG	O
interaction	interaction	NN	O
with	with	IN	O
Trp	Trp	NNP	O
286	286	CD	O
,	,	,	O
while	while	IN	O
the	the	DT	O
terminal	terminal	JJ	O
piperidine	piperidine	NNP	O
group	group	NN	O
located	locate	VBN	O
into	into	IN	O
the	the	DT	O
CAS	cas	NN	O
and	and	CC	O
established	establish	VBD	O
a	a	DT	O
âarene	âarene	JJ	O
-	-	HYPH	O
Hâ	hâ	NN	O
interaction	interaction	NN	O
with	with	IN	O
Trp	Trp	NNP	O
86	86	CD	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
the	the	DT	O
polymethylene	polymethylene	JJ	O
chain	chain	NN	O
was	be	VBD	O
folded	fold	VBN	O
in	in	IN	O
a	a	DT	O
conformation	conformation	NN	O
to	to	TO	O
make	make	VB	O
it	-PRON-	PRP	O
interact	interact	VB	O
with	with	IN	O
the	the	DT	O
mid	mid	JJ	O
-	-	NN	O
gorge	gorge	NN	O
site	site	NN	O
through	through	IN	O
a	a	DT	O
âarene	âarene	JJ	O
-	-	HYPH	O
Hâ	hâ	NN	O
interaction	interaction	NN	O
with	with	IN	O
Tyr	Tyr	NNP	O
341	341	CD	O
.	.	.	O

All	all	PDT	O
these	these	DT	O
results	result	NNS	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
present	present	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
dual	dual	JJ	O
binding	bind	VBG	O
site	site	NN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
AChE	AChE	``	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
in	in	IN	O
agreement	agreement	NN	O
with	with	IN	O
our	-PRON-	PRP$	O
results	result	NNS	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
kinetic	kinetic	NNP	O
analysis.3âD	analysis.3âD	NNP	O
docking	docking	NNP	O
model	model	NN	O
of	of	IN	O
compound	compound	NN	O
4c	4c	CD	O
with	with	IN	O
hAChE.	hache.	JJ	O
Atom	Atom	NNP	O
colours	colour	NNS	O
:	:	:	O
green	green	JJ	O
-	-	HYPH	O
carbon	carbon	NN	O
atoms	atom	NNS	O
of	of	IN	O
4c	4c	CD	O
,	,	,	O
gray	gray	JJ	O
-	-	HYPH	O
carbon	carbon	NN	O
atoms	atom	NNS	O
of	of	IN	O
residues	residue	NNS	O
of	of	IN	O
hAChE	hAChE	NNP	O
,	,	,	O
dark	dark	JJ	O
blue	blue	JJ	O
-	-	HYPH	O
nitrogen	nitrogen	NN	O
atoms	atom	NNS	O
,	,	,	O
red	red	JJ	O
-	-	HYPH	O
oxygen	oxygen	NN	O
atoms	atom	NNS	O
,	,	,	O
yellow	yellow	NN	O
-	-	HYPH	O
sulfur	sulfur	NN	O
atoms	atom	NNS	O
.	.	.	O

2âD	2âd	CD	O
schematic	schematic	JJ	O
diagram	diagram	NN	O
of	of	IN	O
docking	docking	NN	O
model	model	NN	O
of	of	IN	O
compound	compound	NN	O
4c	4c	CD	O
with	with	IN	O
hAChE.	hache.	NN	O
The	the	DT	O
figure	figure	NN	O
was	be	VBD	O
prepared	prepare	VBN	O
using	use	VBG	O
the	the	DT	O
ligand	ligand	NNP	O
interactions	interaction	NNS	O
application	application	NN	O
in	in	IN	O
MOE	MOE	NNP	O
.	.	.	O

It	-PRON-	PRP	O
has	have	VBZ	O
been	be	VBN	O
established	establish	VBN	O
that	that	IN	O
the	the	DT	O
PAS	PAS	NNP	O
mediates	mediate	NNS	O
AChE	AChE	''	O
-	-	HYPH	O
triggered	trigger	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
compounds	compound	NNS	O
capable	capable	JJ	O
of	of	IN	O
interacting	interact	VBG	O
with	with	IN	O
the	the	DT	O
PAS	PAS	NNP	O
may	may	MD	O
have	have	VB	O
the	the	DT	O
ability	ability	NN	O
to	to	TO	O
reduce	reduce	VB	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
.	.	.	O

Because	because	IN	O
our	-PRON-	PRP$	O
compounds	compound	NNS	O
have	have	VBP	O
been	be	VBN	O
demonstrated	demonstrate	VBN	O
to	to	TO	O
be	be	VB	O
dual	dual	JJ	O
binding	bind	VBG	O
site	site	NN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
AChE	AChE	``	O
,	,	,	O
compounds	compound	VBZ	O
4c	4c	NNP	O
-	-	HYPH	O
f	f	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
with	with	IN	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
AChE	AChE	``	O
were	be	VBD	O
also	also	RB	O
selected	select	VBN	O
for	for	IN	O
testing	test	VBG	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
on	on	IN	O
AChE	AChE	''	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
by	by	IN	O
a	a	DT	O
thioflavin	thioflavin	JJ	O
T	T	NNP	O
fluorescence	fluorescence	NN	O
method	method	NN	B
,	,	,	B
.	.	.	O

It	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
seen	see	VBN	O
from	from	IN	O
the	the	DT	O
Table	table	NN	O
4	4	CD	O
that	that	IN	O
,	,	,	O
in	in	IN	O
comparison	comparison	NN	O
to	to	IN	O
the	the	DT	O
reference	reference	NN	O
compound	compound	NN	O
donepezil	donepezil	NNP	O
,	,	,	O
most	most	JJS	O
compounds	compound	NNS	O
can	can	MD	O
efficiently	efficiently	RB	O
inhibit	inhibit	VB	O
the	the	DT	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
with	with	IN	O
inhibition	inhibition	NN	O
rates	rate	NNS	O
ranging	range	VBG	O
from	from	IN	O
12.06	12.06	CD	O
%	%	NN	O
to	to	IN	O
29.02	29.02	CD	O
%	%	NN	O
at	at	IN	O
100âÎ¼M.	100âÎ¼M.	NNP	O
Generally	generally	RB	O
,	,	,	O
compounds	compound	VBZ	O
with	with	IN	O
potent	potent	JJ	O
inhibition	inhibition	NN	O
on	on	IN	O
AChE	AChE	``	O
also	also	RB	O
exhibited	exhibit	VBN	O
high	high	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
.	.	.	O

Compound	Compound	NNP	O
4c	4c	CD	O
that	that	WDT	O
displayed	display	VBD	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
on	on	IN	O
both	both	CC	O
eeAChE	eeAChE	NNP	O
and	and	CC	O
hAChE	hAChE	NNP	O
exerted	exert	VBD	O
the	the	DT	O
strongest	strong	JJS	O
effect	effect	NN	O
on	on	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
.	.	.	O

It	-PRON-	PRP	O
showed	show	VBD	O
the	the	DT	O
inhibition	inhibition	NN	O
rate	rate	NN	O
of	of	IN	O
29.02	29.02	CD	O
%	%	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
donepezil	donepezil	NN	O
.	.	.	O

The	the	DT	O
capacities	capacity	NNS	O
of	of	IN	O
these	these	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
to	to	TO	O
inhibit	inhibit	VB	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1â42	aî²1â42	NN	O
aggregation	aggregation	NN	O
were	be	VBD	O
also	also	RB	O
investigated	investigate	VBN	O
by	by	IN	O
employing	employ	VBG	O
the	the	DT	O
same	same	JJ	O
ThT	ThT	NNP	O
-	-	HYPH	O
based	base	VBN	O
fluorometric	fluorometric	JJ	O
assay	assay	NN	B
.	.	.	O

Curcumin	Curcumin	NNP	O
,	,	,	O
a	a	DT	O
natural	natural	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
,	,	,	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

From	from	IN	O
the	the	DT	O
results	result	NNS	O
summarised	summarise	VBN	O
in	in	IN	O
Table	table	NN	O
4	4	CD	O
,	,	,	O
all	all	DT	O
compounds	compound	NNS	O
exhibited	exhibit	VBN	O
moderate	moderate	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
25âÎ¼M.	25âî¼m.	CD	O
The	the	DT	O
relatively	relatively	RB	O
long	long	JJ	O
linkers	linker	NNS	O
were	be	VBD	O
not	not	RB	O
beneficial	beneficial	JJ	O
for	for	IN	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
,	,	,	O
as	as	IN	O
compounds	compound	NNS	O
4d	4d	NNP	O
-	-	HYPH	O
f	f	NNP	O
showed	show	VBD	O
lower	low	JJR	O
activity	activity	NN	O
than	than	IN	O
their	-PRON-	PRP$	O
short	short	JJ	O
linker	linker	NN	O
analogues	analogue	VBZ	O
4c	4c	NNP	O
and	and	CC	O
9a	9a	NNP	O
-	-	HYPH	O
b	b	NN	O
.	.	.	O

Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
compound	compound	NNP	O
9b	9b	CD	O
with	with	IN	O
dimethyl	dimethyl	JJ	O
groups	group	NNS	O
on	on	IN	O
quinolinone	quinolinone	NNP	O
ring	ring	NN	O
presented	present	VBD	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
with	with	IN	O
inhibition	inhibition	NN	O
rate	rate	NN	O
of	of	IN	O
35.29	35.29	CD	O
%	%	NN	O
at	at	IN	O
25âÎ¼M.	25âî¼m.	CD	O
Since	since	IN	O
most	most	JJS	O
of	of	IN	O
the	the	DT	O
selected	select	VBN	O
compounds	compound	NNS	O
could	could	MD	O
efficiently	efficiently	RB	O
inhibit	inhibit	VB	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
,	,	,	O
their	-PRON-	PRP$	O
possible	possible	JJ	O
binding	bind	VBG	O
modes	mode	NNS	O
with	with	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
were	be	VBD	O
also	also	RB	O
investigated	investigate	VBN	O
by	by	IN	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
.	.	.	O

The	the	DT	O
studies	study	NNS	O
were	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
the	the	DT	O
Molecular	Molecular	NNP	O
Operating	Operating	NNP	O
Environment	Environment	NNP	O
software	software	NN	O
,	,	,	O
and	and	CC	O
compound	compound	NNP	O
9b	9b	CD	O
with	with	IN	O
most	most	JJS	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
aggregation	aggregation	NN	O
was	be	VBD	O
chosen	choose	VBN	O
for	for	IN	O
docking	docking	NN	O
into	into	IN	O
the	the	DT	O
structure	structure	NN	O
of	of	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
5	5	CD	O
,	,	,	O
compound	compound	NNP	O
9b	9b	CD	O
is	be	VBZ	O
transversely	transversely	RB	O
fitted	fit	VBN	O
along	along	IN	O
the	the	DT	O
major	major	JJ	O
helix	helix	NN	O
,	,	,	O
and	and	CC	O
forms	form	VBZ	O
a	a	DT	O
Ï-cation	ï-cation	CD	O
interaction	interaction	NN	O
between	between	IN	O
its	-PRON-	PRP$	O
quinolinone	quinolinone	NN	O
ring	ring	NN	O
and	and	CC	O
Lys	Lys	NNP	O
16	16	CD	O
of	of	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
.	.	.	O

Hydrophobic	hydrophobic	JJ	O
interactions	interaction	NNS	O
also	also	RB	O
play	play	VBP	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
the	the	DT	O
stability	stability	NN	O
of	of	IN	O
9b	9b	NNP	O
/	/	SYM	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
complex	complex	NN	O
.	.	.	O

From	from	IN	O
the	the	DT	O
Figure	Figure	NNP	O
5	5	CD	O
,	,	,	O
it	-PRON-	PRP	O
can	can	MD	O
be	be	VB	O
seen	see	VBN	O
that	that	IN	O
compound	compound	NN	O
9b	9b	CD	O
establishes	establish	VBZ	O
hydrophobic	hydrophobic	JJ	O
interactions	interaction	NNS	O
with	with	IN	O
residues	residue	NNS	O
Leu	Leu	NNP	O
17	17	CD	O
,	,	,	O
Phe	Phe	NNP	O
20	20	CD	O
,	,	,	O
Ala	Ala	NNP	O
21	21	CD	O
,	,	,	O
Val	Val	NNP	O
24	24	CD	O
,	,	,	O
Ile	Ile	NNP	O
31	31	CD	O
,	,	,	O
Leu	Leu	NNP	O
34	34	CD	O
and	and	CC	O
Met	Met	NNP	O
35.3âD	35.3âd	NN	O
docking	docking	NN	O
model	model	NN	O
of	of	IN	O
compound	compound	NN	O
9b	9b	CD	O
with	with	IN	O
AÎ²1	AÎ²1	NNP	O
-	-	HYPH	O
42	42	CD	O
.	.	.	O

Atom	atom	NN	O
colours	colour	NNS	O
:	:	:	O
green	green	JJ	O
-	-	HYPH	O
carbon	carbon	NN	O
atoms	atom	NNS	O
of	of	IN	O
9b	9b	NN	O
,	,	,	O
gray	gray	JJ	O
-	-	HYPH	O
carbon	carbon	NN	O
atoms	atom	NNS	O
of	of	IN	O
residues	residue	NNS	O
of	of	IN	O
AÎ²	AÎ²	NNP	O
,	,	,	O
dark	dark	JJ	O
blue	blue	JJ	O
-	-	HYPH	O
nitrogen	nitrogen	NN	O
atoms	atom	NNS	O
,	,	,	O
red	red	JJ	O
-	-	HYPH	O
oxygen	oxygen	NN	O
atoms	atom	NNS	O
,	,	,	O
yellow	yellow	NN	O
-	-	HYPH	O
sulfur	sulfur	NN	O
atoms	atom	NNS	O
.	.	.	O

2âD	2âd	CD	O
schematic	schematic	JJ	O
diagram	diagram	NN	O
of	of	IN	O
docking	docking	NN	O
model	model	NN	O
of	of	IN	O
compound	compound	NN	O
9b	9b	CD	O
with	with	IN	O
AÎ²	AÎ²	NNP	O
.	.	.	O

The	the	DT	O
figure	figure	NN	O
was	be	VBD	O
prepared	prepare	VBN	O
using	use	VBG	O
the	the	DT	O
ligand	ligand	NNP	O
interactions	interaction	NNS	O
application	application	NN	O
in	in	IN	O
MOE	MOE	NNP	O
.	.	.	O

After	after	IN	O
all	all	RB	O
above	above	IN	O
evaluation	evaluation	NN	O
,	,	,	O
compound	compound	NN	O
4c	4c	CD	O
with	with	IN	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
for	for	IN	O
both	both	DT	O
eeAChE	eeAChE	NNP	O
and	and	CC	O
hAChE	hache	ADD	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
good	good	JJ	O
BBB	BBB	NNP	O
permeability	permeability	NN	O
and	and	CC	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
inhibitory	inhibitory	NN	O
effect	effect	NN	O
was	be	VBD	O
considered	consider	VBN	O
as	as	IN	O
the	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
compound	compound	NN	O
for	for	IN	O
further	further	JJ	O
study	study	NN	O
.	.	.	O

To	to	TO	O
determine	determine	VB	O
whether	whether	IN	O
compound	compound	NN	O
4c	4c	CD	O
have	have	VBP	O
potential	potential	JJ	O
toxicity	toxicity	NN	O
on	on	IN	O
nerve	nerve	NN	O
cells	cell	NNS	O
,	,	,	O
its	-PRON-	PRP$	O
cytotoxicity	cytotoxicity	NN	O
on	on	IN	O
human	human	JJ	O
neuroblastoma	neuroblastoma	NN	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
cells	cell	NNS	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
the	the	DT	O
3â-2	3â-2	CD	O
,	,	,	O
5-diphenyltetrazolium	5-diphenyltetrazolium	CD	O
assay	assay	NN	B
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
6	6	CD	O
,	,	,	O
compound	compound	NNP	O
4c	4c	NNPS	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
a	a	DT	O
significant	significant	JJ	O
effect	effect	NN	O
on	on	IN	O
cell	cell	NN	O
viability	viability	NN	O
at	at	IN	O
doses	dose	NNS	O
up	up	IN	O
to	to	IN	O
100âÎ¼M	100âî¼m	CD	O
,	,	,	O
which	which	WDT	O
indicated	indicate	VBD	O
that	that	IN	O
it	-PRON-	PRP	O
might	may	MD	O
be	be	VB	O
a	a	DT	O
safe	safe	JJ	O
agent	agent	NN	O
for	for	IN	O
treating	treat	VBG	O
AD	ad	NN	O
.	.	.	O

Cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
compound	compound	NNP	O
4c	4c	CD	O
on	on	IN	O
human	human	JJ	O
neuroblastoma	neuroblastoma	NN	O
cells	cell	NNS	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y.	SY5Y.	NNP	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
cells	cell	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
compound	compound	NNP	O
4c	4c	NNP	O
12.5â100âÂµM	12.5â100âÂµM	NNP	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
are	be	VBP	O
shown	show	VBN	O
as	as	IN	O
the	the	DT	O
percentage	percentage	NN	O
of	of	IN	O
viable	viable	JJ	O
cells	cell	NNS	O
after	after	IN	O
treatment	treatment	NN	O
with	with	IN	O
compound	compound	NNP	O
4c	4c	CD	O
vs	vs	IN	O
untreated	untreated	JJ	O
control	control	NN	O
cells	cell	NNS	O
.	.	.	O

Date	date	NN	O
are	be	VBP	O
expressed	express	VBN	O
as	as	IN	O
meanâÂ±âSD	meanââ±âsd	NN	O
from	from	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

Toxicity	toxicity	NN	O
of	of	IN	O
new	new	JJ	O
chemical	chemical	NN	O
entity	entity	NN	O
is	be	VBZ	O
a	a	DT	O
major	major	JJ	O
obstacle	obstacle	NN	O
in	in	IN	O
path	path	NN	O
of	of	IN	O
drug	drug	NN	O
discovery	discovery	NN	O
and	and	CC	O
development	development	NN	B
,	,	,	B
,	,	,	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
compound	compound	NN	O
4c	4c	CD	O
was	be	VBD	O
select	select	JJ	O
for	for	IN	O
acute	acute	JJ	O
toxicity	toxicity	NN	O
study	study	NN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
to	to	TO	O
further	further	RB	O
investigate	investigate	VB	O
its	-PRON-	PRP$	O
safety	safety	NN	O
property	property	NN	O
.	.	.	O

After	after	IN	O
delivering	deliver	VBG	O
compound	compound	NN	O
4c	4c	CD	O
to	to	IN	O
Kunming	Kunming	NNP	O
mice	mouse	NNS	O
with	with	IN	O
different	different	JJ	O
dosages	dosage	NNS	O
625	625	CD	O
,	,	,	O
1250	1250	CD	O
and	and	CC	O
2500âmg	2500âmg	NNPS	O
/	/	SYM	O
kg	kg	NNS	O
by	by	IN	O
oral	oral	NNP	O
administration	administration	NN	O
,	,	,	O
no	no	DT	O
evident	evident	JJ	O
toxicity	toxicity	NN	O
signs	sign	NNS	O
such	such	JJ	O
as	as	IN	O
death	death	NN	O
,	,	,	O
significant	significant	JJ	O
weight	weight	NN	O
loss	loss	NN	O
,	,	,	O
and	and	CC	O
drastically	drastically	RB	O
altered	alter	VBN	O
consumption	consumption	NN	O
of	of	IN	O
water	water	NN	O
or	or	CC	O
food	food	NN	O
,	,	,	O
were	be	VBD	O
observed	observe	VBN	O
during	during	IN	O
the	the	DT	O
two	two	CD	O
-	-	HYPH	O
week	week	NN	O
experimental	experimental	JJ	O
period	period	NN	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
at	at	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
the	the	DT	O
experiment	experiment	NN	O
,	,	,	O
all	all	DT	O
used	use	VBN	O
animals	animal	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
possible	possible	JJ	O
toxic	toxic	JJ	O
damage	damage	NN	O
on	on	IN	O
their	-PRON-	PRP$	O
organs	organ	NNS	O
was	be	VBD	O
also	also	RB	O
examined	examine	VBN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
compound	compound	NN	O
4c	4c	NNPS	O
did	do	VBD	O
not	not	RB	O
cause	cause	VB	O
any	any	DT	O
toxicity	toxicity	NN	O
effect	effect	NN	O
at	at	IN	O
a	a	DT	O
dose	dose	NN	O
up	up	IN	O
to	to	IN	O
2500âmg	2500âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

A	a	DT	O
series	series	NN	O
of	of	IN	O
novel	novel	JJ	O
quinolinone	quinolinone	NNP	O
derivatives	derivative	NNS	O
containing	contain	VBG	O
dithiocarbamate	dithiocarbamate	NN	O
moiety	moiety	NNP	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
as	as	IN	O
multifunctional	multifunctional	JJ	O
AChE	AChE	''	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
AD	ad	NN	O
.	.	.	O

Most	Most	JJS	O
of	of	IN	O
these	these	DT	O
compounds	compound	NNS	O
exhibited	exhibit	VBD	O
potent	potent	JJ	O
eeAChE	eeAChE	NNP	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
excellent	excellent	JJ	O
selectivity	selectivity	NN	O
to	to	IN	O
eeAChE	eeAChE	NNP	O
over	over	IN	O
eqBuChE.	eqbuche.	NN	O
Among	among	IN	O
them	-PRON-	PRP	O
,	,	,	O
compound	compound	NNP	O
4c	4c	CD	O
having	have	VBG	O
a	a	DT	O
four	four	CD	O
-	-	HYPH	O
carbon	carbon	NN	O
atom	atom	NN	O
linker	linker	NN	O
and	and	CC	O
a	a	DT	O
piperidine	piperidine	NN	O
moiety	moiety	NN	O
at	at	IN	O
terminal	terminal	JJ	O
position	position	NN	O
displayed	display	VBD	O
the	the	DT	O
highest	high	JJS	O
activity	activity	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
eeAChE	eeAChE	NNP	O
,	,	,	O
and	and	CC	O
it	-PRON-	PRP	O
was	be	VBD	O
also	also	RB	O
the	the	DT	O
strongest	strong	JJS	O
inhibitor	inhibitor	NN	O
of	of	IN	O
hAChE	hAChE	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
0.16âÎ¼M	0.16âî¼m	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
nearly	nearly	RB	O
3-fold	3-fold	CD	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
tacrine	tacrine	JJ	O
IC50	IC50	NNP	O
=	=	SYM	O
0.47âÎ¼M	0.47âî¼m	NN	O
.	.	.	O

Kinetic	kinetic	JJ	O
and	and	CC	O
molecular	molecular	JJ	O
docking	docking	NN	O
analyses	analysis	NNS	O
revealed	reveal	VBD	O
that	that	IN	O
compound	compound	NN	O
4c	4c	CD	O
was	be	VBD	O
a	a	DT	O
mix	mix	RB	O
-	-	HYPH	O
typed	type	VBN	O
inhibitor	inhibitor	NN	O
able	able	JJ	O
to	to	TO	O
bind	bind	VB	O
simultaneously	simultaneously	RB	O
to	to	IN	O
PAS	PAS	NNP	O
and	and	CC	O
CAS	cas	NN	O
of	of	IN	O
hAChE.	hache.	NN	O
Besides	besides	RB	O
,	,	,	O
compound	compound	NNP	O
4c	4c	NNP	O
presented	present	VBD	O
the	the	DT	O
best	good	JJS	O
ability	ability	NN	O
to	to	TO	O
inhibit	inhibit	VB	O
AChE	AChE	''	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
29.02	29.02	CD	O
%	%	NN	O
at	at	IN	O
100âÎ¼M	100âî¼m	CD	O
and	and	CC	O
could	could	MD	O
efficiently	efficiently	RB	O
inhibit	inhibit	VB	O
self	self	NN	O
-	-	HYPH	O
induced	induce	VBN	O
AÎ²	AÎ²	NNP	O
aggregation	aggregation	NN	O
30.67	30.67	CD	O
%	%	NN	O
at	at	IN	O
25âÎ¼M	25âî¼m	CD	O
.	.	.	O

More	more	RBR	O
importantly	importantly	RB	O
,	,	,	O
it	-PRON-	PRP	O
showed	show	VBD	O
negligible	negligible	JJ	O
toxicity	toxicity	NN	O
to	to	IN	O
SH	SH	NNP	O
-	-	HYPH	O
SY5Y	SY5Y	NNP	O
cells	cell	NNS	O
,	,	,	O
good	good	JJ	O
ability	ability	NN	O
to	to	TO	O
penetrate	penetrate	VB	O
the	the	DT	O
BBB	BBB	NNP	O
and	and	CC	O
no	no	DT	O
significant	significant	JJ	O
acute	acute	JJ	O
toxicity	toxicity	NN	O
in	in	IN	O
mice	mouse	NNS	O
at	at	IN	O
doses	dose	NNS	O
up	up	IN	O
to	to	IN	O
2500âmg	2500âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

Overall	overall	RB	O
,	,	,	O
we	-PRON-	PRP	O
propose	propose	VBP	O
that	that	IN	O
compound	compound	NN	O
4c	4c	CD	O
is	be	VBZ	O
a	a	DT	O
promising	promise	VBG	O
candidate	candidate	NN	O
deserved	deserve	VBN	O
for	for	IN	O
further	further	JJ	O
study	study	NN	O
.	.	.	O

